University of Massachusetts Amherst

ScholarWorks@UMass Amherst
Open Access Dissertations
2-2013

Regulation and Action of Skp2 and Rhoa in Cell and Tumor
Models: Investigation into the Molecular Mechanisms
Responsible for the Aggressive Phenotype of Triplenegative
Breast Cancer
Katrina D. Fagan-Solis
University of Massachusetts Amherst

Follow this and additional works at: https://scholarworks.umass.edu/open_access_dissertations
Part of the Molecular Biology Commons

Recommended Citation
Fagan-Solis, Katrina D., "Regulation and Action of Skp2 and Rhoa in Cell and Tumor Models: Investigation
into the Molecular Mechanisms Responsible for the Aggressive Phenotype of Triplenegative Breast
Cancer" (2013). Open Access Dissertations. 683.
https://doi.org/10.7275/r4p6-1b63 https://scholarworks.umass.edu/open_access_dissertations/683

This Open Access Dissertation is brought to you for free and open access by ScholarWorks@UMass Amherst. It
has been accepted for inclusion in Open Access Dissertations by an authorized administrator of
ScholarWorks@UMass Amherst. For more information, please contact scholarworks@library.umass.edu.

REGULATION AND ACTION OF SKP2 AND RHOA IN CELL AND TUMOR
MODELS: INVESTIGATION INTO THE MOLECULAR MECHANISMS
RESPONSIBLE FOR THE AGGRESSIVE PHENOTYPE OF TRIPLENEGATIVE BREAST CANCER

A Dissertation Presented
by
KATERINA D. FAGAN-SOLIS

Submitted to the Graduate School of the
University of Massachusetts Amherst in partial fulfillment
of the requirements for the degree of
DOCTOR OF PHILOSOPHY
February 2013
Molecular and Cellular Biology Graduate Program

!

© Copyright by Katerina D. Fagan-Solis 2013
All Rights Reserved

!

Regulation and Action of SKP2 and RhoA in Cell and Tumor Models: Investigation
into the Molecular Mechanisms Responsible for the Aggressive Phenotype of TripleNegative Breast Cancer

A Dissertation Presented
By
KATERINA D. FAGAN-SOLIS

Approved as to style and content by:

__________________________________________
Kathleen F. Arcaro, Chair

__________________________________________
Brian T. Pentecost, Member

__________________________________________
Sallie Smith Schneider, Member

__________________________________________
Barbara A. Osborne, Member

________________________________________
Barbara A. Osborne, Director
Molecular and Cellular Biology Graduate Program

!

DEDICATION

To my Mama, Vivian Solis-Fagan and my best friend and sister Karlie Vavrinek. Without
the two of you I would not have started or finished this journey. Here’s to boats,
retirement, and a family compound!

!

ACKNOWLEDGMENTS

My sincere thanks go first to my advisor, Dr. Kathleen Arcaro. Kathleen took me
on in her lab after a twenty minute “interview” that was a surprise to both of us, and all
we talked about was that I was from Albany, NY and did my undergraduate studies at
SUNY Albany and she did her post-graduate work at SUNY Albany. Absolutely no
science talk occurred, however when asked to take me on for the summer as part of a
research program she did not hesitate. Kathleen has been a great mentor and a model of
the type of scientist that I wish to be. She has been supportive, understating, attentive,
and instrumental in my graduate training.
I also thank my committee members. I have immense respect for Dr. Pentecost,
Dr. Smith Schneider, and Dr. Osborne as scientists and mentors, and I deeply appreciate
that they’ve served on my committee. They have contributed greatly to my graduate
research though experimental and personal guidance.
I also have been blessed with some awesome lab mates throughout my time here.
Dr. Joseph Gozgit started the Arcaro lab down the road of breast cancer research and his
research directly led into mine. Dr. Lauren Moffatt, Eva Browne, Kristin Williams,
Elizabeth Punska, Stephanie Zimmers, and Kasie Auger provided great company both
inside and outside the lab, and in many instances comic relief.
I thank the MCB program, specifically Sarah Czerwonka and Doreen Fifield for
keeping me on track on the administrative side and for letting me crash in the MCB
conference room for numerous meetings, lunches, and to write or study. I’d also like to
thank the VASCI department, of which the Arcaro Lab is a part, including the faculty,
staff and students for providing me with a supportive environment.

v

I thank Dr. Amy Burnside, for learning alongside me how to optimize cell cycle
analysis on the departmental FACS analysis equipment. For his statistical expertise, I
thank Dr. Douglas Anderton. I’d also like to acknowledge the laboratory of Dr. Sallie
Smith Schneider, whose space I frequently invaded and took advantage of their expertise.
I also like to especially thank Kelly Gauger for teaching me invasion assays and
Elizabeth Henchey for running my mouse studies (sorry for the long nights). My many
thanks go to Brooke Bentley and Sharon Marconi for their histology work. I also like to
recognize Dr. Christopher Otis for collaborating with me on my pathology work.
I’d also like to recognize the Northeast Alliance for Graduate Education & the
Professoriate (NEA). NEA funded me on numerous occasions throughout my graduate
career, which allowed me to continue my research without having to TA or worry about
funding. I also printed out countless posters for various conferences for myself (and on
occasion lab mates). Special thanks to the NEA team Sandy Petersen, Millicent Jackson,
Marlina Duncan, and Michael Alderman.
I have made a number of good friends during my time at UMASS who have
supported me in every way imaginable. Thank you to incredible friends Eva Browne,
Lindsey Lindequest, Erin Welbey, Anna Alves, and Lauren Moffatt, for filling the years
with laughter and happiness.
My family is, has, and always will be my primary source of joy, support, and
unconditional love. My mother, Vivian Solis-Fagan, has been nothing short of critical in
all of my successes. She is the one who started me on the path of learning and discovery.
Through her I discovered that secondary education is not only possible but also critical
for a successful future. Anyone who knows her understands why I look up to her as my

vi

role model for how to learn, live, and love. Thanks to my father, Howard Fagan, and my
siblings, Jabbar, Kia, Howard, Elijah, and my niece Makayla who taught me how to deal
with many different personalities, to be a strong and independent person and who have
likewise given me love and support.
My greatest thanks go to Karlie Vavrinek. Karlie and I have been best friends and
closer than sisters for over thirty years. She has been my rock. She keeps me balanced
between work and play. She has kept me sane and has seen me through good times
(accomplishments, awards, graduations) and bad times (lab frustrations, medical
procedures and anxiety induced sickness). I can count on her for anything and
everything. She was always there with a kind word or a motivating comment when I
swore that I was ready to quit she would always bring things back into prospective.
Without her I don’t know what I would do. From the bottom of my heart to the best
friend a person could ever have, I love you and thank you.
Last but not least I’d like to thank God for without my faith I would not be the
person I am today. Glory be to God in the highest.

vii

ABSTRACT
REGULATION AND ACTION OF SKP2 AND RHOA IN CELL AND TUMOR
MODELS: INVESTIGATION INTO THE MOLECULAR MECHANISMS
RESPONSIBLE FOR THE AGGRESSIVE PHENOTYPE OF TRIPLENEGATIVE BREAST CANCER
FEBRUARY 2013
KATERINA D. FAGAN-SOLIS, B.S., STATE UNIVERSITY OF NEW YORK AT
ALBANY
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Kathleen F. Arcaro

Breast cancer tops the list of new cancer cases and is predicted to be the second
leading cause of cancer deaths in women in 2012. The primary objective of the present
study was to provide insights into the molecular mechanisms underlying the aggressive
growth and metastasis of triple-negative and basal-like breast cancers. To study
increased growth and invasive behavior in triple-negative and basal-like breast cancers
we utilize both an interesting and relevant cell culture model and examination of human
tissue.
In this study, we use the Tamoxifen-selected, MCF-7 derivative, TMX2-28 breast
cancer cell line. TMX2-28 cells are triple-negative in that they lack expression of the
estrogen receptor alpha (ERα), progesterone receptor (PR), and human epidermal growth
factor receptor 2 (HER2). They also have acquired a mixed basal/luminal cytokeratin
profile, suggestive of a more basal-like phenotype. TMX2-28 cells are highly
proliferative and invasive.
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In addition to our cell culture model, we also examine human tissue. Thirty
frozen breast carcinoma samples were evaluated for mRNA expression. Additionally, I
analyzed protein expression, using immunohistochemistry (IHC), of 50 benign reduction
mammoplasty and 188 breast tumors (formalin-fixed paraffin embedded). Of the 188
breast tumors, 93 were ERα-positive and 95 were ERα-negative. Of the 95 ERα-negative
samples, 24 were further classified as non-triple negative (either PR or HER2 positive),
49 were classified as triple-negative, and 22 were not further classified due to
unavailability of HER2 status and were used only in analyses of ERα-negative tumors.
Thirty-seven of the 188 tumor samples were ductal carcinoma in situ, 138 were invasive
ductal carcinomas, and 13 were classified as other. Lastly, 23 of the 188 tumors were
grade 1, 48 were grade 2, 105 were grade 3, and 12 did not have grade data available.
S-phase kinase-associated protein 2 (SKP2) plays an important role in cell cycle
regulation by targeting p27 for degradation. The cyclin-dependent kinase (CDK)
inhibitor p27 regulates G1/S transition by binding cyclin/CDK complexes and abrogating
its activity. By targeting p27 for degradation, SKP2 frees the complexes needed to
progress into the S phase of the cell cycle. Evaluation of SKP2 expression in TMX2-28
revealed significantly higher levels than in other breast cancer cell lines. Despite the high
levels of SKP2 expression, p27 protein was not reduced. However, levels of the Serine
10 phosphorylated form of p27 (pSer10p27), which has been associated with increased
proliferation rates, was found to be increased. Furthermore, suppression of SKP2
completely eliminated the pSer10p27 and slowed cycle progression confirming the role
of SKP2 in the aggressive growth of TMX2-28 cells.
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Assessment of mRNA from 30 frozen human breast cancers demonstrated that
SKP2 is more highly expressed in ERα-negative and basal-like breast cancers.
Immunohistochemical analysis of 188 breast cancers and 50 benign reduction
mammoplasty tissues confirmed that SKP2 is more highly expressed in ERα-negative
breast cancers and for the first time demonstrated that triple-negative breast cancers are
more likely to overexpress SKP2 than are non-triple-negative, but still ERα-negative,
tumors. In contrast to some previous reports, we did not observe an inverse relationship
between SKP2 and p27 expression. Only 11% of tumors expressed high SKP2 and low
p27, while 32% of tumors had high SKP2 and high p27. Although no significant
relationship between SKP2 and p27 expression was observed in human breast cancers, a
significant positive relationship was discovered between SKP2 and pSer10p27.
Furthermore, high levels of SKP2 and pSer10p27 were observed significantly more often
in ERα-negative and triple negative breast tumors than in ERα-positive breast cancers.
Based on these results and those of the cell culture experiments showing complete
elimination of pSer10p27 after suppression of SKP2 it appears that levels of pSer10p27
may be a better indicator of SKP2-dependent p27 degradation than are levels of p27.
Therefore, that inhibiting SKP2 in triple-negative breast cancers expressing high levels of
both SKP2 and pSer10p27 regardless of p27 levels may be a valid therapeutic approach.
A foremost threat to patients is tumor invasion and metastasis, with the greatest
risk to patients diagnosed with triple-negative and basal-like breast cancers. Two distinct
morphological/functional mechanisms are known for single cell migration in tissues:
mesenchymal and amoeboid invasion. Mesenchymal movement involves the use of
proteases that cause cellular lysis in tissues, thereby creating a path through which cells
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can invade. Amoeboid movement is protease-independent; cells find paths through the
ECM by pushing and squeezing through regions of adequate size. Despite their invasive
phenotype, TMX2-28 retains morphology similar to non-aggressive MCF-7 cells,
suggesting that their invasion may be proteolytic-independent.
We determined that TMX2-28 lack MMP-1 mRNA, and MMP-2/MMP-9 protein
expression; each of which is important in protease-dependent invasion. Furthermore,
TMX2-28 cells have low expression of other genes key to protease-dependent invasion
including Slug, Zeb 1, Zeb 2, Vimentin, Fibronectin and N-cadherin. RhoA is a member
of the Rho superfamily of GTPases that acts as a molecular switch to control signal
transduction and is critical to the amoeboid invasion mechanism. TMX2-28 cells have
high expression of protease-independent invasion genes such as RhoA, ROCK 1, ROCK
2, and E-cadherin. Finally, treating TMX2-28 cells with a RhoA pathway inhibitor or an
shRNA targeting RhoA significantly reduces their invasiveness. These data suggest that
TMX2-28 cells use a RhoA-dependent, proteolytic-independent invasion mechanism.
Collectively, the data presented here demonstrate the roles of SKP2 and RhoA in triplenegative and basal-like breast cancers, making both genes, as well as their pathways,
desirable therapeutic targets.
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CHAPTER 1

INTRODUCTION
Breast Biology and Breast Cancer Statistics
The breast is composed of glands, named lobules, which are responsible for milk
production, and ducts that connect the lobules to the nipple (Figure 1.1). The remainder
of the breast is made up of fatty, connective, and lymphatic tissue (1). Cancer is a disease
characterized by uncontrolled growth and spreading of abnormal cells. Breast cancer
originates in the breast in either lobular or ductal cells (2, 3). Two types of breast cancer
exist; in situ cancers are confined within ducts or lobules while invasive or infiltrating
breast cancers began in lobules or ducts but has succeeded in migrating beyond the site of
origin (2, 3).
Breast cancer is estimated to top the list of new cancer cases and to be the second
leading cause of cancer deaths in women in 2012. An estimated 227,000 women will be
diagnosed with breast cancer this year and approximately 40,000 will die as a result of
their breast cancer (Figure 1.2) (4). In recent years, incidence rates of breast cancer have
been steadily increasing among all races (Figure 1.3 Top). Incidence rates are higher in
non-Hispanic white women compared to African Americans in most age groups.
However African American women have higher incidence rates before the age of forty
and are more likely to die of breast cancer at every age. (Figure 1.3 Bottom) (5).

The Discovery of Breast Cancer Subtypes
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The development of gene expression profiling in 2000 using cDNA microarray
technology has led to the identification of five breast tumor subtypes with distinct
molecular signatures and each correlated with different clinical outcomes (Figure 1.4) (610). Luminal A and luminal B subtypes are defined by expression of estrogen receptor α
(ERα) and luminal cell cytokeratins (CK) 8 and 18. The luminal A subtype typically has
greater ERα expression and has a favorable outcome while the luminal B subtype
expresses less ERα and has intermediate outcome. The ERBB2+ subtype is characterized
by over expression of human epidermal growth factor receptor 2 (HER2) and has poor
overall outcome. The normal-like tumor subtype is ERα-negative and has high
expression of some basal epithelium markers including CK 5 and 17. Lastly, the basal or
basal-like tumors are ERα negative and have high expression of basal cell markers
including CK 5 and 17. Basal-like tumors are highly aggressive and generally have poor
patient outcome (7, 11).
A new subtype of breast cancer, termed the triple-negative subtype, was brought
to the forefront of research in 2005. Triple-negative breast cancers were defined as
tumors that lack expression of ERα, Progesterone Receptor (PR), and HER2 (12). While
the majority of triple-negative tumors also express basal cell markers, and the majority of
basal-like cancers are also triple-negative (13-15), it is noteworthy to mention that
clinical, microarray, and immunohistochemical data show that these tumor types are not
entirely the same and thus cannot be lumped together into one subtype (16). Patients
with triple-negative breast cancer face poor prognosis, as their tumors will not respond to
anti-estrogen nor anti-HER2 therapies (17, 18). Rather than conventional cytotoxic
therapies, designing individualized treatment for specific subgroups of disease is
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necessary and requires targeting genes or pathways actively engaged in the
pathophysiology of the breast cancer subtype.

The Hallmarks of Cancer
In 2000, Douglas Hanahan and Robert Weinberg proposed that six biological
capabilities are acquired during the development of human cancer (Figure 1.5). These
hallmarks of cancer are distinctive and complimentary and enable cancer cells to grow
and metastasize (19). Importantly, they provide cancer researchers with a foundation in
which to understand the diverse biology of cancer. The six hallmarks consist of: 1.
Sustaining proliferative signaling. 2. Evading growth suppressors. 3. Activating
invasion and metastasis. 4. Enabling replicative immortality. 5. Inducing angiogenesis.
6. Resisting cell death. Since this this landmark publication, a number of other cell
processes have emerged as potential hallmarks including reprograming of energy
metabolism, and evading immune destruction (20). The research described in this
dissertation involves sustaining proliferation signaling through dysregulation of the cell
cycle and activating invasion and metastasis.

The Cell Cycle and SKP2
The cell cycle comprises a series of tightly controlled events that drive the
replication of DNA and cell division. Cyclins, cyclin dependent kinases (CDK) and
CDK inhibitors regulate cell cycle progression by controlling the transitions between cell
cycle phases. Formation of specific cyclin/CDK complexes is required for phase
transitioning as these complexes target substrates involved in the transition process (2123). CDK inhibitors are negative regulators of the cell cycle. They act through binding
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to CDKs and blocking the formation of cyclin/CDK complexes, thus preventing the
progression of the cell cycle. Dysregulation of the cell cycle results in uncontrolled cell
proliferation in particular the G1/S transition. Abnormal regulation of the proteins
involved in these processes is more than likely to be pivotally involved in cancer
development and progression (19, 24).
S-phase kinase-associated protein 2 (SKP2) is an F-box protein and is component
of the SKP1-Cullin1-F-box (SCF)/E3-ligase complex (25). The F-box proteins of SCF
complexes are variable and function as receptors for specific target proteins and promote
their degradation (26). SKP2 is the specific factor of the SCFSKP2/E3 ligase (Figure 1.6
A) and is involved in cell cycle progression through degradation of p27 (25, 27). In
normal cells, SKP2 targets a number of proteins including the negative cell cycle
regulator p27 for ubiquitin-mediated degradation (28). During the transition from G1 to S
phase, p27 undergoes phosphorylation modifications at three major sites, Serine 10
(Ser10), Threonine 187 (Thr187) and Threonine 198 (Thr198) (29). Phosphorylation at
Ser10, catalyzed by KIS and MIRK kinases, stabilizes p27 in quiescent cells; however,
this phosphorylation event has been shown to promote cell proliferation (29-32). Thr198
phosphorylation is catalyzed by ROCK 1 kinase, only when Ser10 is already
phosphorylated, and results in the inactivation of both free and CDK bound p27 (33, 34).
Lastly, phosphorylation of Thr187 is catalyzed by SKP2 and promotes the ubiquitin
ligase-mediated degradation of p27 (Figure 1.7) (21, 28, 35-39). p27 is a cyclin
dependent kinase (CDK) inhibitor that regulates the G1/S transition by binding
cyclin/CDK complexes, specifically Cyclin E/CDK2 and Cyclin A/CDK2 complexes,
and abrogating their actions, thus promoting progression into the S phase of the cell cycle
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(Figure 1.6 B) (21, 35, 36). Because SKP2 is responsible for the degradation of p27, SKP2
is thought to function as an oncoprotein and high protein levels have been associated with
triple-negative and basal-like tumors (16, 40).

Invasion, Metastasis and RhoA
Metastasis is dependent upon cancer cells being able to invade surrounding
extracellular matrix (ECM) and adapt to different microenvironments within the primary
tumor, the ECM, blood and/or lymphatic systems, and finally, to establish a new niche in
a distant tissue (41-43). The proteins that control cell-cell and ECM interactions are
thought to play a role in tumor cell invasion and metastasis by controlling cell
morphology, motility, and interactions with the tumor microenvironment (41, 44). Thus,
such proteins provide attractive therapeutic targets.
Two distinct morphological/functional mechanisms are known for single cell
migration in tissues: fibroblast-type mesenchymal invasion, and leucocyte-type amoeboid
invasion. Mesenchymal movement is characterized by an elongated cellular shape, and
involves the use of proteases that cause cellular lysis in tissues, thereby creating a path
through which cells can invade (44-48). In this kind of motility, cell speed is relatively
slow (0.1-1 µm/min) and is dependent on actin polarization and lamellipodium formation
for directionality of cell movement (49, 50). Amoeboid migrating cells have a rounded
morphology and their movement is protease–independent (Figure 1.8). Instead, cells find
paths through the ECM by pushing and squeezing through regions of adequate size (43,
44, 47, 48, 51, 52). In this kind of motility, cells exploit the propulsory forces resulting
from acto-myosin cytoskeleton contractility, which results in very high migratory speeds
(up to 4 µm/min). Amoeboid movement occurs independently of cell polarization but
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requires RhoA-ROCK signaling to promote the rapid remodeling of the cell cortex (45,
51, 53, 54).
Migration of cancer cells is dependent on Ras Homolog Gene Family, Member A
(RhoA) signaling (43, 44, 47, 51, 52). RhoA is a member of the Rho superfamily of
GTPases that acts as a molecular switch to control signal transduction (Figure 1.9 A)
(55). It carries out its actions through activation of its two targets: Rho-associated, coiledcoil containing protein kinase (ROCK) 1 and ROCK 2, which in turn regulate different
facets of actin dynamics including stress fiber assembly, cell contraction, actin-filament
stabilization, and focal adhesion organization (Figure 1.9 B) (56-59).
The role of RhoA and its effector ROCK in mesenchymal motility is complex;
their activity needs to be reduced to extend protrusion at the front of the cell but they
promote the retraction of the lagging end (50, 60). However, the overall effect of
inhibiting RhoA/ROCK in mesenchymal cells is often minimal (51). Conversely, RhoA
activity is critical to the amoeboid invasion mechanism (53, 61-63). Up-regulation of
RhoA mRNA and protein is well documented for a variety of human cancers and has
been positively correlated with cancer metastasis (64-66).

A Triple-Negative Breast Cancer Cell Line Model
In this study, we use the Tamoxifen-selected, MCF-7 derivative, TMX2-28 breast
cancer cell line. TMX2-28 cells have lost expression of the estrogen receptor (ERα) and
have acquired a mixed basal/luminal cytokeratin profile, suggestive of a more basal-like
phenotype (67-69). Morphologically, TMX2-28 cells retained an epithelial cell shape
similar to MCF-7. Behaviorally, TMX2-28 cells are highly proliferative (Figure 1.10 A)
and invasive (Figure 1.10 B) (67, 68). It is these characteristics that make TMX2-28 cells
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an interesting and relevant model for studying increased growth and invasive behavior in
triple-negative and basal-like breast cancers. Studies of TMX2-28 cell cultures have
guided our investigation of proteins expressed in human breast cancer.
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(http://www.cancer.gov/cancertopics/screening/understanding-breast-changes/allpages#2)

Figure 1.1 Anatomical structure of the human breast (1).
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Figure 1.2 Leading new cancer cases and deaths; 2012 estimates. Breast cancer is
estimated to top the list of leading new cancer cases and to be the second leading cause of
cancer deaths in women in 2012. An estimated 227,000 women will be diagnosed with
breast cancer this year and approximately 40,000 will die as a result of their breast cancer
(4, 5).
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(American Cancer Society, Inc., Surveillance Research 2012)

Figure 1.3 Breast cancer incidence and mortality rates. (Top) Age-specific female breast
cancer incidence (2004 – 2008) and mortality (2003 – 2007) rates. Incidence rates of
breast cancer have been steadily increasing among all races. (Bottom) Trends in female
breast cancer incidence by race and ethnicity, US, 1975 – 2008. Rates are higher in nonHispanic white women compared to African Americans in most age groups. African
American women have higher incidence rates before the age of forty and higher death
rates at all ages (5).
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(Sorlie et. al. 2003)

Figure 1.4 Identification of five breast tumor subtypes with distinct molecular signatures.
Expression of ERα and luminal cell CKs 8 and 18 define luminal A and luminal B
subtypes. The luminal A subtype typically has greater ERα expression and has a
favorable outcome while the luminal B subtype expresses less ERα expression and has
intermediate outcome. The ERBB2+ subtype is characterized by over expression of
HER2 and has poor overall outcome. The normal-like tumor subtype is ERα-negative
and has high expression of some basal epithelium markers including CK 5 and 17.
Lastly, the basal or basal-like tumors are ER negative status and have high expression of
basal cell markers including CK 5 and 17. Basal-like tumors are highly aggressive and
generally have poor patient outcome (9).
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(Hanahan & Weinberg 2000)

Figure 1.5 The Hallmarks of Cancer (19).
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A

B

(Modified from Duensing et. al. 2009; Magori et. al. 2011)

Figure 1.6 SKP2 protein structure and mechanism. (A) SKP2 is a component of the
SCFSKP2 complex and promotes progression into the S-phase of the cell cycle by
regulating p27. (B) In proliferating cells, SKP2 targets p27 for ubiquitin-mediated
degradation. By targeting p27 for degradation, SKP2 promotes progression into the Sphase of the cell cycle. p27 abrogates the actions of cyclin/CDK complexes thereby
preventing the G1-S transition and inhibiting the cell cycle (70, 71).
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Figure 1.7 Model of p27 phosphorylation. During the transition from G1 to S phase, p27
undergoes phosphorylation modifications at three major sites, Serine 10 (Ser10),
Threonine 187 (Thr187) and Threonine 198 (Thr198) (29). Phosphorylation at Ser10,
catalyzed by KIS and MIRK kinases, stabilizes p27 in quiescent cells; however, this
phosphorylation event has been shown to promote cell proliferation (29-32). Thr198
phosphorylation is catalyzed by ROCK 1 kinase, only when Ser10 is already
phosphorylated, and results in the inactivation of both free and CDK bound p27 (33, 34).
Lastly, phosphorylation of Thr187 is catalyzed by SKP2 and promotes the ubiquitin
ligase-mediated degradation of p27 (21, 28, 35-39).
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(Condeelis & Segall 2003)

Figure 1.8 Morphological/functional mechanisms for single cell migration in tissues,
fibroblast-type mesenchymal invasion and leucocyte-type amoeboid invasion (72).
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A

B

(Riento et. al. 2003; Voth et. al. 2005)

Figure 1.9 RhoA protein structure and mechanism. (A) Protein structure of RhoA
kinase. (B) Rho acts as a molecular switch to control signal transduction in cells. Its
main targets are the Rocks (1 & 2), which regulate difference facets of actin dynamics
(73, 74).
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(Gozgit et. al. 2006; 2007)

Figure 1.10 TMX2-28 cells are (A) highly proliferative and (B) invasive (67, 68).
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CHAPTER 2

S-PHASE KINASE-ASSOCIATED PROTEIN 2 (SKP2) OVEREXPRESSION IS
ASSOCIATED WITH INCREASED SERINE 10-PHOSPHORYLATED p27
(pSer10p27) IN TRIPLE-NEGATIVE BREAST CANCERS

Introduction
Breast cancer is the most common female malignancy, and the second leading
cause of cancer related death in the U.S. (75). Breast cancer patients with disease of
similar stage and grade often respond differently to therapy resulting in disparate clinical
outcomes. The development of gene expression profiling, using cDNA microarray
technology, has led to the identification of several subgroups of breast cancers with
distinct molecular signatures (7, 11). Historically, only estrogen receptor α (ERα),
progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) have
been widely accepted as predictive factors and are used to dictate a patient’s therapeutic
regime (76).
Approximately 70% of breast cancers express ERα and are termed ERα-positive
(77). For these patients, targeted endocrine therapy with anti-estrogens is available and
their tumors are often responsive. The remaining 30% of breast cancers do not express
ERα and are classified as ERα-negative (77). ERα-negative breast cancers are more
aggressive, and have been further classified by molecular profiling into two biologically
different subtypes, triple-negative and basal-like subtypes (7, 11). Triple-negative tumors
lack ERα, PR, and HER2 expression while basal-like tumors are typically triple-negative
but are also associated with positive basal cytokeratin (CK) 5, 14, and/or 17 expression

18

patterns (7, 16, 78-80). Basal or basal-like tumors are also ERα-negative but have high
expression of basal cell markers including CK 5 and 17. Triple-negative and basal-like
tumors are highly aggressive and generally have poor patient outcome as patients with
these subtypes have tumors that will not be responsive to anti-estrogen or anti-HER2
therapies (7, 11, 17, 18). Rather than treating patients with conventional cytotoxic
therapies, designing individualized treatment for specific subgroups of disease is
necessary and requires targeting genes or pathways actively engaged in the
pathophysiology of breast cancer.
Dysregulation of the cell cycle results in uncontrolled cell proliferation. In
particular, the G1/S transition, and aberrant regulation of the proteins involved in this
process are pivotally involved in cancer development and progression (19, 24). S-phase
kinase-associated protein 2 (SKP2) plays an important role in cell cycle regulation, and
was originally identified as part of a SCF ubiquitin-protein ligase complex though its
interaction with Cyclin A during S phase of the cell cycle (35). SCF complexes have
three core components, SKP1, Cullin/cdc53, Rbx1/Roc, and an F-box containing protein
that confers its name (Figure 1.6). SKP2 serves as the F-box component of the SCFSKP2
complex and governs its specificity (81). p27 is a cyclin dependent kinase (CDK)
inhibitor that regulates the G1/S transition by binding cyclin/CDK complexes, specifically
Cyclin E/CDK2 and Cyclin A/CDK2 complexes, and abrogating their actions. In normal
cells, SKP2 targets a number of proteins including p27 for ubiquitin-mediated
degradation, thus promoting progression into the S phase of the cell cycle (21, 28, 35,
36). During the transition from G1 to S phase, p27 undergoes phosphorylation
modifications at three major sites, Serine 10 (Ser10), Threonine 187 (Thr187) and
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Threonine 198 (Thr198) (29). Phosphorylation at Ser10 (pSer10p27) stabilizes p27 in
quiescent cells, however pSer10p27 has been shown to promote cell proliferation (2932). Thr198 phosphorylation (pThr198p27) is catalyzed by ROCK 1 kinase, only when
Ser10 is already phosphorylated, and results in the inactivation of both free and CDK
bound p27 (33, 34). Lastly, phosphorylation of Thr187 (pThr187p27) is catalyzed by
SKP2 and promotes the ubiquitin ligase-mediated degradation of p27 (21, 28, 35-39).
SKP2 has oncogenic potential and its overexpression has been found in several
cancers, including thyroid, oral epithelial, colorectal, lymphomas, non-small cell lung
carcinoma, melanoma, and Kaposi’s sarcomas (40, 82-89). Emerging evidence has
demonstrated that SKP2 overexpression significantly promotes the transition from G1 to
S phase of the cell cycle, resulting in accelerated proliferation, making this process
critically involved in the pathogenesis of breast cancer (89-93). Overexpression of SKP2
has been associated with poor prognosis on its own (94) and in combination with high
Cyclin E expression (92) as well as other unfavorable prognostic factors including
increased tumor grade, lack of expression of ERα and PR, and HER2 overexpression (95,
96). High SKP2 expression has been shown to be a hallmark of triple-negative, basallike tumors (16). Additionally, SKP2 expression was found to have an inverse
relationship to p27 expression levels (94, 95, 97-99). However, to date eight published
studies have examined the relation between SKP2 and p27 expression in breast cancer
and reported mixed results. Of the two largest studies, one did not observe an inverse
relationship between SKP2 and p27 (92, 100), while other found the relationship to have
little prognostic value (96).
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Given the inconsistency in the literature regarding the relationship between SKP2,
p27 and prognosis, the extent to which overexpression of SKP2 results in increased
phosphorylation of p27 and cell proliferation in breast cancer is uncertain. Therefore, we
directly examined SKP2, p27, and Ser10-phosphorylated p27 (pSer10p27) in human
breast cancers. We also examined the expression of the related pathway cell cycle genes,
CDK2 and Cyclin E, as well as Cyclin D1. Additionally, we examined SKP2 and related
proteins in MCF-7-derived TMX2-28 cells that are triple-negative and have a mixed
basal/luminal CK profile (68, 69). Suppression of SKP2 in these cells provided an
opportunity to examine the function of SKP2 in the development of triple-negative,
basal-like breast cancers.

Materials and Methods
Cell Culture: TMX2-28 and MCF-7 cells were maintained in T-75 culture flasks
in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with cosmic calf serum
(5%), insulin (10 µg/ml), non-essential amino acids (100X), penicillin-streptomycin
(10,000 µg/ml), and L-glutamine (200 mM) at 37°C and 5% CO2. TMX2-28-NC,
TMX2-28-S2, and TMX2-28-MC cells were maintained as above with the addition of 2.5
µg/ml Puromycin to the culture medium. MDA-MB-231 cells were maintained in L-15
medium supplemented with 10% FBS at 37°C and 0% CO2. SKBR-3 cells were
maintained in McCoy’s 5A medium supplemented with 10% fetal bovine serum (FBS) at
37°C and 5% CO2. All cells were passaged when near 80% confluence.

RNA and Protein Isolation: Total RNA (n=3 biological samples) was isolated
with Tri-Reagent (Molecular Research Center, Cincinnati, OH) according to
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manufacturer’s suggestions and protocols as previously described (67, 68, 101). RNA
was treated with Turbo DNA-Free (Ambion, Austin, TX) to remove any DNA
contamination; RNA quality was assessed by 260/280 nm spectrophotometer readings
(Nanodrop 8000; Thermo Scientific, Wilmington, DE). Protein- containing cell lysates
were isolated from cell cultures (n=3 biological samples) with pre-chilled SDS lysis
buffer (1% SDS, 0.06 M Tris-HCL, and 10% glycerol) according to our standard
laboratory protocols (67, 68, 101). Extracts were used for Western immunoblotting.

Western Immunoblotting: Protein lysates were mixed with NuPage sample
buffer and reducing agent (Invitrogen, Carlsbad, CA), heated at 70°C for 10 min,
separated on Mini-PROTEAN TGX gels (Bio-Rad, Hercules, CA) and then transferred to
an Immuno-Blot polyvinylidene difluoride membrane (Bio-Rad, Hercules, CA) according
to manufacturer’s protocols. Membranes were incubated in blocking buffer (5% nonfat
dry milk/Tris buffered saline and 0.1% Tween 20) for 1 hour at room temperature with
gentle shaking. Membranes were then incubated with primary antibodies, [SKP2 (1:200;
sc-7164), Cyclin D1 (1:200; sc-753), Cyclin E (1:200; sc-198), p27 (1:200; sc-528)
(polyclonal; Santa Cruz Biotechnology, Santa Cruz, CA); CDK2 (1:500; ab6538;
polyclonal) and pSer10p27 (1:10,000; ab62364; monoclonal) (Abcam, Cambridge, MA)],
overnight at 4°C, followed by incubation with the secondary antibody, anti-rabbit IgG
linked to horseradish peroxidase (1:1000; 7074S; Cell Signaling Technology, Danvers,
MA), for 1 hour at room temperature. Chemiluminescent signals were detected with
SuperSignal West Pico Kit (Peirce, Rockford, IL), and imaged using the G.BOX Chemi
HR-16 (Syngene, Fredrick, MD). Membranes were stripped using Restore stripping
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buffer (Thermo Scientific, Rockford, IL) and reprobed for gleceraldehyde-3-phosphate
(GAPDH; 1:10,000; 5174; Cell Signaling Technology, Danvers, MA).

Quantitative Real-Time Reverse Transcriptase PCR (qRT-PCR): RNA samples
(n=3 biological samples) were reverse transcribed and amplified using the One Step RTPCR kit (Qiagen, Valencia, CA) in the Roche LightCycler (Roche, Indianapolis, IN).
Total RNA (75 ng) was incubated with Qiagen RT-PCR master mix including primers
(25µM each) and SYBR Green I nucleic acid stain (2X; Invitrogen, Carlsbad, CA,
product number S7563) in pre-cooled capillaries (Roche, Indianapolis, IN) and was
reversed transcribed (50°C for 30 min). Following reverse transcription, samples were
heated to 95°C for 15 min to activate the HotStar Taq DNA polymerase and to
simultaneously inactivate the reverse transcriptase. The generation of amplified products
was monitored over 45 PCR cycles by fluorescence of intercalating SYBR Green. Each
cycle consisted of the following steps: 1. Denaturation at 95°C for 15 sec. 2. Annealing
at 60°C for 15 sec. 3. Extension at 72°C for 30 sec. Relative mRNA levels were
normalized to hypoxanthine ribosyltransferase (HPRT) levels to control for RNA quality
and concentration. Gene specific primers that span an exon-exon junction, designed
using Primer3 software (http://frodo.wi.mit.edu/), and purchased from Integrated DNA
Technologies, Inc. (Coralville, IA), were used for ERα, PR, HER2, SKP2, p27, CDK2,
Cyclin E, Cyclin D1, and HPRT (Table 2.1).

RNA Interference: pGIPz lentiviral shRNAmir (Open Biosystems, Lafayette,
CO) targeted against SKP2 (Source ID: V2LHS_199552) or a negative control (random
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sequence with no significant homology to any endogenous human, mouse or rat gene)
pGIPz lentiviral shRNAmir were transfected into TMX2-28 cells using Superfect
Transfection Reagent (Qiagen, Valencia, CA) per manufacturer’s instructions. Fortyeight hours post transfection; cells were treated with selection medium (DMEM
supplemented with 2.5 µg/ml Puromycin). Five days following initial selection, cells
transfected with the negative control shRNAmir were seeded at low density into 100 mm
culture dishes and cultured until small colonies formed (<50 cells). Cloning cylinders
(BellCo Glass, Inc. Vineland, NJ) were used to isolate colonies resulting from a single
clone to create the TMX2-28-NC (Negative Control) cell line. Cells transfected with the
shRNAmir targeting SKP2 were split into two populations. One population of cells was
kept and termed TMX2-28-MC (Mass Culture), and the other population was seeded at
low density into 100 mm culture dishes and cultured until small colonies formed (<50
cells). Cloning cylinders (BellCo Glass, Inc. Vineland, NJ) were used to isolate colonies
resulting from a single clone to create the TMX2-28-S2 (SKP2 knockdown) cell line.

Cell Cycle Analysis: Adherent cells cultures were harvested by trypsinization,
resuspended in phosphate buffered saline (PBS), and fixed with 95% ethanol (ETOH) at
4°C overnight. Fixed cells were resuspended in staining solution (PBS, 2 mM MgCl2, 10
µg/ml RNase A, 100 µg/ml propidium iodide) and incubated at 37°C for 20 minutes.
Single cell populations (1x106 cells/ml) were analyzed using FACSDiva 4.1 and cell
cycle analysis was performed using BD FACSDiva software (Becton-Dickinson
Bioscience, Franklin Lakes, NJ).
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Human Tissue: Institutional Review Board approval was obtained from Baystate
Medical Center and the University of Massachusetts at Amherst. Samples were
identified numerically to maintain patient anonymity. For the mRNA analysis of SKP2
and cytokeratins, 30 frozen breast tumor samples were retrieved from Baystate Medical
Center, Department of Surgical Pathology as previously described (67, 68, 101). For the
immunohistochemistry of SKP2 and related proteins, 159 tumor and 40 reduction
mammoplasty (RM) tissues were stained. These tissues were obtained as follows: six
sections were cut from each of five tissue microarrays (TMAs) containing a total of 101
tumor and 40 RM cases represented in triplicate as previously described (101), and six
slides from each of 58 formalin-fixed paraffin-embedded (FFPE) breast tumors were
purchased from University of Massachusetts Medical School Cancer Tissue Bank,
Worcester, MA. An additional 29 tumor cases and 10 RM blocks were stained and
scored for SKP2 only as previously described (102). The combined tumor cases = 188
and RM = 50. Clinical pathology reports accompanied all cases providing data on age,
tissue type, histological grade, and ERα, PR, and HER2 status when available. Table 2.2
provides an over view of the clinical and pathological characteristics of the reduction
mammoplasty and breast carcinoma patients.

Immunohistochemistry (IHC): Immunohistochemical study was performed
using the Dakocytomation LSAB2 System-HRP kit (Dako, Carpinteria, CA) as
previously described (101). Primary antibodies for the IHC were the same as those used
for the Western immunoblotting, with IHC-specific dilutions as follows: SKP2 (1:25),
Cyclin D1 (1:200), Cyclin E (1:200), p27 (1:200) (polyclonal; Santa Cruz Biotechnology,
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Santa Cruz, CA); CDK2 (1:1000; polyclonal) and p27 (phosphor S10; 1:50; monoclonal;
Abcam, Cambridge, MA), with secondary antibody anti-rabbit from Dako (Dako polymer
K4003; Dako, Carpinteria, CA). Slides were stained with diaminobenzidine (DAB)
chromogen for 10 minutes. The slides were then counterstained for 15 seconds in
Mayer’s hematoxylin, transferred to glacial acetic acid water for 15 seconds, and then to
ammonia water to blue. Finally, slides were dehydrated in ETOH and xylene before
manual coverslipping.
The performance of each antibody was optimized through the use of negative (no
primary antibody) and positive (tonsil, skeletal muscle, or breast cancer tissues with
known protein positivity) controls and by testing a series of dilutions bracketing the
manufacturer’s suggested dilutions. Antigen retrieval methods (Sodium citrate, pH,
EDTA) were also optimized. Western immunoblotting was performed to confirm protein
specificity based on protein size.

Review of IHC Sample Staining and Pathology: Scoring was conducted by one
anatomic pathologist (CNO) without knowledge of the hormone receptor status of
samples. TMAs and tissue slides were scored for immunoreactivity of all six proteins,
assigning values of negative, weak, moderate, or strong for the intensity of staining.
Tissues in which immunoreactivity was scored as weak, moderate or strong were further
evaluated for the distribution of the staining and received descriptors of focal or diffuse
for high and low percentage of cells stained respectively. While the number of cells
showing immunoreactivity was not counted, tissue in which it appeared that greater than
50% of the cells were stained was scored as diffuse. Tissue in which it appeared that less
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than 50% of the cells were stained was scored as focal, and in general these tissues had
less than 10% of the cells stained. Tissues scored as negative were not evaluated for
focal versus diffuse distribution. Scoring occurred over twelve sessions during which a
single observer (KDF-S) recorded all evaluations. Periodically, previously evaluated
slides were included in the blinded scoring session resulting in a total of ten different
tumors being independently scored three times (three tumors for SKP2, two for p27, two
for pSer10p27 and one each for Cyclin E, CDK2 and Cyclin D1). Of these thirty repeat
scores, there was only one discrepancy: a tumor was scored once as moderate/diffuse and
twice as strong/diffuse for p27.

Statistical Analyses: Cell cycle and mRNA expression data were analyzed and
graphed with GraphPad Prism Version 3.02 (GraphPad Software, Inc., San Diego, CA).
For ANOVA and post hoc two-tailed comparisons, significance was set at p<0.05. A
Bonferonni correction was used to adjust the p-value whenever multiple t-tests were
conducted.
For analysis of the immunohistochemistry results the intensity scores of negative,
weak, moderate and strong were converted to two metrics: positive (including weak,
moderate and strong) versus negative (including negative only) and high (including
moderate and strong) versus low (including negative and weak). For each case in the
TMAs, the highest score given to any of the three punches was used for analysis. For the
slides, scores were based on evaluation of all tumor or RM tissue. Analysis also was
conducted on the descriptors of diffuse and focal, as well as the original scores of
negative, weak, moderate and strong, providing a total of four metrics that were analyzed.
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Relationships between protein levels and hormone status, tumor grade, and tumor type
were assessed with two-tailed Fisher Exact tests and p-values are presented. For tumor
type and grade the original evaluations of negative, weak, moderate and strong were used
in the analysis. Relationships between protein levels and age were assessed with
regression analysis on the original evaluations of negative, weak, moderate and strong.
STATA 11.2 (Statacorp LP, College Station, TX) was used for analysis of IHC data.

Results
Characterization of TMX2-28 receptor status
ERα, PR, and HER2 expression are the most important prognostic factors for
breast cancer, dictating a patient’s therapeutic regime. Prior studies have shown that
TMX2-28 cells lack expression of ERα and have many characteristics of basal-like breast
tumors (Chapter 1) however the status of PR and HER2 expression was not examined
(67, 69). To determine the triple-negative receptor status of TMX2-28 cells, ERα, PR,
and HER2 expression was analyzed by qRT-PCR and IHC. When compared to its
ERα/PR positive parent cell line, MCF-7, triple-negative cell line MDA-MB-231, and the
ERα/PR negative, HER2 overexpressing cell line SKBR-3, it is clear that TMX2-28 cells
not only lack expression of ERα, but also lack expression of PR and HER2 (Figure 2.1),
making them a triple-negative breast cancer cell line.

SKP2 is overexpressed in the triple-negative breast cancer cell line, TMX2-28
High levels of SKP2 protein in breast cancers have been associated with poor
prognosis, ERα- and HER2-negative status, and basal cell markers (92, 94, 99). To
determine whether the triple-negative, Tamoxifen-selected TMX2-28 cells have
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increased levels of SKP2 we compared mRNA and protein levels among three breast
cancer cell lines, TMX2-28, MCF-7, and MDA-MB-231. The mRNA and Western
immunoblot analyses demonstrated that SKP2 expression was significantly higher in
TMX2-28 cells (Figure 2.2 A). SKP2 mRNA levels in TMX2-28 cells were roughly six
times greater than in the parent cell line MCF-7 and the aggressive MDA-MB-231 cell
line. These data suggest TMX2-28 may be a good model for studying the aggressive
nature of a subset of triple-negative breast cancers that have high SKP2 and basal-like
phenotypes.

Overexpression of SKP2 regulates expression of its pathway genes in TMX2-28
SKP2 controls cell cycle progression through regulation of p27. SKP2 targets
p27 for degradation, which allows the formation of CDK2/Cyclin E complexes and
entrance of the cell into the S phase of the cell cycle (16-18). We have shown that
TMX2-28 cells overexpress SKP2, next we sought to determine the expression of other
genes involved in this pathway. The mRNA and protein expression of the SKP2 pathway
genes, p27, pSer10p27 (protein only), CDK2, and Cyclin E, as well as the expression of
Cyclin D1, a cell cycle gene not involved in the SKP2 pathway, was determined using
qRT-PCR and Western immunoblotting. Since TMX2-28 cells have higher expression of
SKP2 than do MCF-7, we expected TMX2-28 to have lower levels of p27 protein, due to
increased phosphorylation. Contrary to our prediction, TMX2-28 cells had significantly
higher p27 mRNA and protein levels than did either MCF-7 or MDA-MB-231 (p<0.05;
Figure 2.3 A). As expected, however, protein levels of pSer10p27, the form of p27
tagged for degradation, was present at substantially higher levels in TMX2-28 than in
other cell lines (Figure 2.3 A). The targets of p27 inhibition, Cyclin E and CDK2 were
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also overexpressed in TMX2-28 as compared to MCF-7 cells (p<0.05 & p<0.01
respectively; Figure 2.3 B & C), while the levels of the non-SKP2 pathway gene, Cyclin
D1, were similar among all cell lines (p>0.05; Figure 2.3 D).
To determine whether the overexpression of SKP2 alters the expression of genes
in the p27 S phase transition, we assessed the effects of suppressing SKP2 expression in
TMX2-28 cells. For this study, TMX2-28 cells were stably transfected with either a
negative control shRNA or an shRNA targeted against SKP2. The resulting lines were
termed TMX2-28-NC (negative control), TMX2-28-S2 (single clone SKP2 knockdown),
and TMX2-28-MC (mass culture SKP2 knockdown). As shown in Figure 2.2 B, we were
able to reduce SKP2 gene expression by approximately 83% in both knockdown lines;
suppression was confirmed by Western immunoblotting. Expression of p27, pSer10p27,
CDK2, Cyclin E, and Cyclin D1 was determined in the three cell lines. Knockdown of
SKP2 resulted in a significant (p<0.001) increase of p27 gene expression that was
reflected in an increase in protein expression (Figure 2.3 A). In agreement with this
finding, pSer10p27 protein levels decreased in TMX2-28-S2 cells compared to the
negative control. Although not significant, there was a slight increase in Cyclin E gene
expression and protein levels confirmed this (Figure 2.3 B). SKP2 knockdown in
TMX2-28 cells also resulted in a significant increase in CDK2 gene and protein
expression and as expected, gene and protein expression of Cyclin D1 remained
consistent (p>0.05; Figure 2.3). TMX2-28-MC cells mirrored TMX2-28-S2 cells in their
expression profiles.
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Knockdown of SKP2 alters cell cycle in TMX2-28
To further investigate the role played by SKP2 overexpression in the control of
cell cycle in breast cancer, TMX2-28-NC, TMX2-28-S2, and TMX2-28-MC cells were
subjected to fixation, staining with propidium iodide, and subsequent cell cycle analysis.
Suppression of SKP2 in both the clonally selected and mass culture cell lines resulted in a
noticeable shift of the cell cycle towards G0/G1 (Figure 2.4). We found a significant
increase in the percentage of cells in the G0/G1 phase and a significant decrease in the
percentage of cells in the S phase of the cell cycle. We did not, however, see a
significant change in the percentage of cells in the G2/M phase of the cell cycle. The
results from this experiment point to a prominent role of SKP2 in the proliferative
potential of TMX2-28 cells.

SKP2 gene expression is higher in basal-like human breast cancers
We examined SKP2 mRNA expression in 30 frozen breast carcinoma samples by
qRT-PCR to determine the extent to which expression patterns detected in the triplenegative, basal-like TMX2-28 cells reflect those of breast cancer. Eighteen ERα-positive
and twelve ERα-negative breast cancers were assessed for mRNA expression of SKP2
and basal cytokeratins 5 and 17 (Figure 2.5). Tumors expressing CK5 and/or 17 were
classified as basal cytokeratin expressing. ERα-negative tumors that also expressed CK 5
and/or 17 were classified as basal-like tumors. Data revealed that there was a marginally
significant trend towards higher SKP2 expression in ERα-negative tumors (n=12) over
ERα-positive (n=18; p=0.067). When tumors were classified by expression of basal
cytokeratins, tumors expressing CK 5 and/or 17 (n=11) also expressed significantly
higher SKP2 mRNA levels than tumors that did not express basal cytokeratins (n=19;
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p=0.038). Additionally, significantly higher SKP2 expression was found in tumors
classified as basal-like (ERα-negative and expressing basal cytokeratins) (n=6) than nonbasal-like (n=24; p=0.043). These results correspond well with the SKP2 overexpression
in our TMX2-28 cell model.

SKP2 and phosphorylated p27 are overexpressed in triple-negative breast cancers
SKP2, p27, pSer10p27, CDK2, Cyclin E, and Cyclin D1 expression was
examined immunohistrochemically using tissue microarrays and tissue slides. We
evaluated protein nuclear staining characteristics of benign RM epithelial cells and of
tumor epithelial cells. Figure 2.6 provides examples of breast cancer cases that received
scores of negative, weak, moderate, or strong based on staining intensity.
Table 2.3 provides a summary of the protein expression in human breast tissue.
Scores of negative, weak, moderate, and strong were converted to two metrics: positive
versus negative and high versus low (described in detail in the methods section). Tissues
with immunoreactivity were further evaluated for distribution of staining and received
scores of diffuse or focal, representing high and low percentage of cells stained
respectively. Immunohistochemical analysis of 238 breast tissue specimens revealed that
SKP2 protein is predominantly expressed in breast cancer (59%; 111 out of 188) as
compared to RM tissue (8%; 4 out of 50; p<0.001). Of the tumors evaluated for
distribution of SKP2 immunoreactivity, 21% (21 out of 98) were scored as diffuse.
Breast cancer cases were classified by ERα status and ERα-negative tumors were
further stratified by triple-negative status. Note that for 22 ERα-negative tumors, HER2
status was unavailable and therefore these cases were excluded from triple-negative
analyses. SKP2 was expressed significantly more often in ERα-negative tumors than in
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ERα-positive tumors: 84% of ERα-negative tumors were positive for SKP2 while only
33% of ERα-positive tumors were positive for SKP2 (p<0.001). Similar results were
obtained when immunoreactivity was analyzed by high/low: 63% of ERα-negative
tumors had high SKP2 expression while only 16% of ERα-positive tumors had high
SKP2 (p< 0.001). Additionally, of the tumors scored for staining distribution, 28% of
ERα-negative tumors had diffuse staining whereas only 6% of ERα-positive tumors were
scored diffuse (Table 2.3).
Among ERα-negative tumors, triple-negative tumors were more likely to be
positive for SKP2 than were non-triple-negative tumors: 98% versus 75%, respectively
(p=0.002), and the staining intensity was more frequently scored as high in triplenegative tumors than it was in non-triple negative tumors (80% versus 58%, respectively;
p=0.056). Furthermore, triple-negative tumors were significantly more likely to be
scored as having a high percent of cells with immunoreactivity for SKP2: 40% of triplenegative tumors were scored as having diffuse SKP2 expression, while 0% of non-triple
negative were scored as having diffuse SKP2 expression (p=0.003).
SKP2 expression has been inversely correlated with p27 levels in subsets of breast
cancer with poor prognosis (94, 95, 97-99). Therefore, since we observed higher levels
of SKP2 in ERα-negative and triple-negative tumors, we expected these groups of tumors
to have low p27 immunoreactivity. In contrast to our expectation, p27 expression was
not lower in ERα-negative or triple-negative tumors; indeed there was no significant
relationship between any of the p27 scoring metrics and hormone receptor status. The
lack of relationship between p27 and hormone receptor status was not due to low p27
expression, as tumors were scored positive (92%), high (69%) and diffuse (61%) for p27

33

immunoreactivity. In contrast to SKP2, p27 expression was common in RM tissue but
still at significantly lower levels than in cancer when analyzed as both positive/negative
and high/low (p=0.040 and p<0.001, respectively; Table 2.3).
SKP2 promotes the ubiquitin-mediated proteolysis of p27 through
phosphorylation, which targets it for degradation via the proteasome pathway (28), yet no
study has examined levels of phosphorylated p27 in breast cancer. Analysis in 192 breast
tissue specimens showed that pSer10p27 protein is more frequently expressed in breast
cancer (50%) as opposed to RM tissue (24%; p= 0.006). Of the 80 tumors scored
positive for pSer10p27, 34% had diffuse staining.
Given the high levels of SKP2 in ERα-negative and triple-negative tumors, we
predicted that pSer10p27 would also be high in these tumors. As predicted, pSer10p27
expression was significantly greater in ERα-negative than in ERα-positive tumors when
assessed by either positive/negative or high/low immunoreactivity (Table 2.3: p<0.001
for both comparisons). However, staining distribution (diffuse versus focal) did not
differ with ERα status. When categorized by triple-negative status, there were no
significant differences in pSer10p27 expression or staining distribution.
All three of the remaining cell cycle genes, Cyclin E, CDK2 and Cyclin D1, were
expressed primarily in cancer as opposed to RM tissue (Table 2.3). Despite the higher
levels in cancer, when evaluated as high/low, most tumors, regardless of hormone status,
were scored as low for Cyclin E. Likewise the majority of tumors were scored low for
CDK2. In contrast, Cyclin D1 was scored as positive and high more frequently in ERαpositive cancers, and was more likely to be scored as low in triple-negative cancers.
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Expression of SKP2 and phosphorylated p27 are highly correlated
Relationships between SKP2 and other proteins are presented in Table 2.4 in
which the total number of tumors staining positive or negative, and high or low for SKP2
are presented, along with the percentage and number of those tumors that were scored
positive (left side of table) or high (right side of the table) for each of the cell cycle genes.
Analysis of 159 tumors in which data were available for both SKP2 and p27 revealed no
significant relationship between the two proteins, either when the analysis was conducted
on positive/negative or high/low scores. In contrast, phosphorylated p27 levels were
positively associated with SKP2 expression. Comparing the relationship between SKP2
and pSer10p27 for high/low staining shows that of the 98 SKP2-positive tumors, 66
(67%) were also positive for pSer10p27. In contrast, of the 61 SKP2-negative tumors,
only 14 (23%) were positive for pSer10p27. Another way of expressing the relationship
between SKP2 and pSer10p27 is to consider that of the 80 tumors positive for
pSer10p27, 66 or 83% were positive for SKP2. The positive relationship between SKP2
and pSer10p27 was highly significant (p<0.001; n=159) as was the relationship when
data were analyzed using high/low scores (p< 0.001; n=159). Furthermore, ERαnegative and triple negative tumors were more likely to be scored high for both SKP2 and
pSer10p27 than were ER-positive cancers (data not shown; Fisher’s Exact < 0.001 for
both comparisons).
Higher levels of SKP2 were associated with increased Cyclin E expression, for
both metrics analyzed (p=0.035 and p=0.04). CDK2 on the other hand, was more likely
to be scored high in tumors that were scored low for SKP2 (p=0.031). There was no
relationship between SKP2 and Cyclin D1 expression. Examples of the
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immunoreactivity observed for SKP2 and related proteins are shown in Figures 2.7
through 2.10; cases are provided of both when SKP2 expression was high and low.
Previous research suggests that high levels of SKP2 and Cyclin E together with
low levels of p27 may occur more frequently in triple negative tumors and may be a
biomarker for poor prognosis (92). While we did not find a relationship between p27 and
SKP2, it remains feasible that the combined expression pattern could be an indicator of
prognosis. Despite small sample sizes, we found that the pattern of high SKP2 and
Cyclin E with low p27 was significantly more common in triple negative tumors than in
ERα-negative tumors that were not triple negative (data not shown; Fisher’s Exact =
0.008).

SKP2 is more highly expressed in ERα-negative and triple-negative tumors from
younger women while pSer10p27, Cyclin D1, p27, and CDK2 are more highly
expressed in tumors from older women

The relationship between strong protein expression and age are presented in Table
2.5. SKP2 expression in tumors was inversely correlated with age (p=0.005; n=159).
When tumors were categorized by ERα status, SKP2 expression was inversely correlated
with age in ERα-negative tumors only (p= 0.014; n=75). Further stratification of ERαnegative tumors revealed that SKP2 immunoreactivity was more frequently scored as
strong in younger women with triple-negative tumors (p=0.029; n=49), but not in
younger women with non-triple negative tumors (p=0.84; n=18). While expression of
SKP2 was generally stronger in younger women, age explained little of the variability in
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SKP2 expression, either when the analysis was conducted on all tumors (R2=0.05), ERαnegative tumors (R2=0.08), or triple-negative tumors (R2=0.1).
In contrast to SKP2, immunoreactivity of p27, pSer10p27, CDK2 and Cyclin D1
was positively correlated with age. Analyses on the total tumor set revealed a trend for
stronger staining in older women for pSer10p27 (p=0.003; n=159) and Cyclin D1
(p=0.012; n=158), this trend was also significant in ERα-negative tumors (pSer10p27:
p=0.004; n=75 and Cyclin D1: p=0.006; n=84), and for Cyclin D1 in triple-negative
(p=0.017; n=49). Strong immunoreactivity of p27 was positively correlated with age
among non-triple negative tumors only (p=0.018l; n=18), while the association between
strong CDK2 immunoreactivity and age was significant among ERα-negative tumors
only (p=0.032; n=71). There was no significant relationship between Cyclin E
expression and age.

SKP2 is more highly expressed in invasive and high grade tumors
The relationship between tumor type or grade and protein immunoreactivity is
presented in Table 2.6 and Table 2.7 respectively. Invasive ductal carcinomas (IDC)
were more likely to have strong SKP2 staining then were ductal carcinomas in situ
(DCIS; p=0.018; n=188). Furthermore, strong SKP2 expression was more frequently
associated with grade three tumors than with lower grade tumors (p=0.010; n=188). The
only other association between cell cycle protein expression and tumor type or grade was
for CDK2, which was more likely to be strongly expressed in DCIS than in IDC tumors
(p<0.001; n=159).
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Discussion
Patients with triple-negative and basal-like tumors face poor prognosis, as their
tumors are not responsive to anti-estrogen or anti-HER2 therapies (17, 18). The
progression of these hormone receptor negative breast cancers may be significantly
impacted by dysregulation of cell cycle regulatory proteins. SKP2 is a component of the
E3 ligase SCFSKP2 complex, and functions as a receptor to specific target proteins
initiating their degradation and promoting cell cycle progression (25, 27, 103). High
expression of SKP2 has been associated with aggressive cancers including the basal-like
breast cancer subtype (16, 94-96). While several researchers have suggested that SKP2 is
a suitable therapeutic target for breast cancer, the subset of breast cancers that will
respond to treatment with inhibitors of SKP2 has not been clearly identified.
The primary objective of the present study was to provide insight into the
oncogenic role of SKP2 in triple-negative and basal-like breast cancers. To accomplish
this, we first validated the triple-negative status of the ERα-negative, basal-like breast
cancer cell line, TMX2-28. Next we learned that, unlike the parent MCF-7 cell line, or
the triple-negative, aggressive MDA-MB-231 cell line, TMX2-28 express high levels of
SKP2, befitting of a triple-negative and basal-like breast tumor model. Based on the
well-known role of SKP2 in p27 degradation we expected TMX2-28 cells to have low
levels of p27 protein. However, both mRNA and protein levels of p27 were significantly
higher in TMX2-28 cells than in either of the cell lines with low SKP2 expression. This
finding led us to ask whether SKP2 was targeting p27 for degradation in TMX2-28 cell
cultures. We found significantly higher levels of pSer10p27 in TMX2-28 as compared to
other cell lines. Furthermore, suppression of SKP2 in TMX2-28 cells using RNAi
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techniques resulted in significantly decreased levels of pSer10p27, increased levels of
p27, and importantly, a slowing of cell cycle progression as evidenced by an increase in
the percentage of cells in the G1/G0 and a decrease in the percentage of cells in S phase of
the cell cycle.
To our knowledge, TMX2-28 is the only breast cancer cell line that is triplenegative and naturally expresses high levels of SKP2, a hallmark of basal-like phenotype
(16). In a study of four breast cancer cell lines transfected with SKP2, Sonoda and
colleagues (99) reported a ‘marked’ decrease in p27 protein. However, from the Western
blots shown in the publication, the decrease in p27 protein appears to be quite modest.
The continued, albeit lower, expression of p27 protein in the presence of high SKP2
expression is in agreement with our findings from TMX2-28 cells indicating that levels
of p27 protein may not be the best biomarker of SKP2-dependent degradation of p27. On
the other hand, the results may simply highlight the need for more accurate quantification
of p27 protein levels; a problem we will encounter again with the IHC data. However, as
we showed in Figure 2.2A, while suppression of SKP2 results in a detectable increase in
p27 protein, it also results in the complete elimination of pSer10p27, clearly
demonstrating the value of assessing pSer10p27 levels.
TMX2-28 cells were derived from MCF-7 cells treated with Tamoxifen. To some
extent, this selection process mimicked the progression that occurs in many women, for
whom after prolonged treatment with Tamoxifen their tumors become resistant to the
drug and they develop ERα-negative breast cancer. Signoretti and colleagues (94)
reported that MCF-7 cells arrested in G1 by combined Tamoxifen treatment and estrogen
deprivation showed increased expression of SKP2, and suggested that deregulated SKP2
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may play a role in the development of resistance to anti-estrogens. The extent to which
overexpression of SKP2 in TMX2-28 cells was critical to the development of Tamoxifen
resistance or is a consequence of loss of ERα is unknown. However, in human tissue
SKP2 overexpression has been associated, although not consistently, with ERα-negative
breast cancers. In the present study, using real time qRT-PCR and tissue from 30 frozen
breast cancers, we found SKP2 mRNA more frequently overexpressed in ERα-negative,
basal-cytokeratin-expressing, and basal-like breast cancers. Since SKP2’s role in
regulating p27 expression occurs post translation, we next examined protein expression in
formalin-fixed breast tissue.
Based on the published literature, the relationship between SKP2 and p27 protein
expression in breast cancer subtypes and its relevance to prognosis is unclear. In 2002
Signoretti and colleagues (94) examined cDNA microarrays of 89 breast cancers and
discovered that high levels of SKP2 were more frequent in ER-negative (11 of 18) as
compared to ER-positive tumors (16 of 71), and that a small subset of cancers (five) with
the highest levels of SKP2 were ER-, PR- and HER2-negative. They then used IHC to
examine a new set of 84 breast cancers for expression of SKP2, p27, Ki67, and ER
proteins (but not HER2). Again, higher levels of SKP2 were observed in ER-negative
tumors (12 of 18) as compared to ER-positive tumors (7 of 47). Among the 19 tumors
that had high levels of SKP2 expression, p27 was significantly more likely to be low (18
of 19). Both high SKP2 and low p27 expression were associated with poor survival, but
a univariate analysis including expression of both proteins found no independent
prognostic value of SKP2 expression, and no improved prognostic ability of the
combination. Still, the authors concluded that SKP2 has oncogenic potential that it is
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overexpressed in a subset of ER- and HER2-negative breast tumors, that inhibition of
SKP2 is a valid therapeutic goal, and that more studies are needed.
Since the publication by Signoretti et. al., seven additional studies examining the
expression of SKP2 and p27 in breast cancer have been published. In 2005, two studies
of 82 (97) and 50 (98) breast cancers found expression of SKP2 to be significantly higher
in ER-negative tumors, and to be inversely correlated with p27 expression. A year later
Traub and colleagues (100) reported that 34% of the 338 breast cancers they examined
had high SKP2 and low p27 and this combined ‘risk factor’ was significantly associated
with a poorer outcome as compared to tumors with all other combinations of SKP2 and
p27 expression patterns. However, contrary to the first three studies, they found no
association between SKP2 expression and ER status. Furthermore, they found SKP2
levels to be higher in HER2-positive breast cancers. In another study published the same
year, Sonoda and coworkers (99) examined SKP2 mRNA levels in 167 breast cancers, of
which they selected 137 for IHC analysis of both SKP2 and p27. Based on the IHC
analysis they reported SKP2 expression to be inversely correlated with p27, and based on
the mRNA analysis they reported SKP2 to be associated with poorer survival and to be
an independent indicator of prognosis. They also were the first to report higher SKP2
expression in tumors of younger women. In the three studies published in 2008, one
study reported no relationship between SKP2 and p27 expression among 438 breast
cancers (92), another study reported an inverse relationship between SKP2 and p27
among 40 breast cancers (95), while the third and largest study of 1598 breast cancers
reported a significant inverse relationship: among the 313 breast cancers positive for
SKP2 a greater percentage (66 %) had low levels of p27 (96). Interestingly, the authors
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of the largest study found no predictive or prognostic value of the inverse relationship
and did not recommend routine assessment of SKP2 and p27 for node-negative early
breast cancer.
In our analysis of 159 tumors for which we had IHC results for both SKP2 and
p27, we found no relationship between the expression levels of SKP2 and p27. Eleven
percent of tumors expressed high SKP2 and low p27, while 32% of tumors had high
SKP2 and high p27. Furthermore, there was no relationship between p27 and ERα or
triple-negative status, even though our sample included 95 ERα-negative and 49 triplenegative breast cancers (the largest sample of triple-negative and third largest sample of
ERα-negative breast cancers among published results). Given the range of previous
results discussed above, our findings are in agreement with some aspects of some
previous reports, but not others. For example, we are the first to confirm the findings of
Sonoda and colleagues showing that younger women tend to have higher expression of
SKP2 (99).
Our most important finding, however, was not about the relationship between
SKP2 and p27 expression. In contrast to our findings on p27, we found expression of
SKP2 to be significantly positively correlated with pSer10p27 in human breast cancers.
Furthermore, the combination of high levels of SKP2 and high pSer10p27 were observed
significantly more often in ERα-negative and triple negative breast tumors than in ERαpositive breast cancers. We learned from the cell culture data that suppressing SKP2 in
our triple-negative breast cancer model TMX2-28 reduced the phosphorylation of p27 at
Ser10 and slowed the cell cycle, while the level of p27 was high both before and after
SKP2 knockdown. Therefore, inhibiting SKP2 in triple-negative and basal-like breast
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cancers that express high levels of both SKP2 and pSer10p27, regardless of p27 levels,
may be an appropriate therapeutic approach.
It appears from the cell culture and IHC studies that levels pSer10p27 may be a
better indicator of SKP2-dependent p27 degradation than are levels of p27. But why are
pSer10p27 levels more closely associated with SKP2 expression than are p27 levels? We
considered whether inconsistencies in relationship between SKP2 and p27 in the
published literature could be due to differences and difficulties in scoring
immunoreactivity (See Appendix A). In all of the eight studies that examined p27 and
SKP2 expression in breast cancer, “low p27” was defined as less than 50% of the cells
showing anti-p27-immunoreactivity (92, 94-100). However, the cutoffs used to define
SKP2 expression varied among these same eight studies. Depending upon the study,
SKP2 expression was considered “high” or “positive” if greater than 5% (100), 10% (92,
94-96, 98) or 50% (97, 99) of cells showed immunoreactivity to the SKP2 antibody.
Considerable variability was observed in number of tumors expressing SKP2 and p27.
The percentage of tumors that were scored low for p27 ranged from 20 (95) to 64 (100),
while the percentage of tumors scored high for SKP2 ranged from 20 (96) to 65 (97).
Surprisingly, one of the papers with the highest cut-off for defining SKP2
immunoreactive cells (>50%) reported the greatest percentage of tumors with high SKP2
(97). In none of these studies was intensity of the immunoreactivity considered even
though intensity of staining is part of the validated “Allred score” for evaluating hormone
receptor status in breast cancer (104) and intensity is routinely used in analysis of protein
expression in pathological tissue (67, 68, 101, 105).
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In the present study, immunoreactivity of all six proteins was scored for both
intensity (negative, weak, moderate, strong) and distribution (diffuse and focal),
providing a total of four metrics for analysis (described in detail in the methods). Our
metric of diffuse and focal corresponds roughly with greater and less than 50% of cells
showing immunoreactivity; therefore it useful to compare results from this metric with
published reports. Limiting our results to diffuse and focal we still find no significant
relationship between SKP2 and p27 and a highly positive relationship between SKP2 and
the pSer10p27. It is unlikely that inconsistencies in scoring alone account for the closer
association between SKP2 and pSer10p27 or the differences in results among the
published studies.
Other factors, such as low levels but hyperactive SKP2, have been proposed to
explain the inconsistent relationship between SKP2 and p27 and prognosis. Additionally
p27 inactivation could occur through cytoplasmic sequestration, which is known to occur
in other tumors (106-108) and which would result in low nuclear p27 staining that was
independent of SKP2 expression. Alternatively p27 expression in breast cancer may be
partially regulated by currently unknown mechanisms. Decreased expression of p27 is
associated with poor clinical outcome in breast cancer (109-111). Decreased expression
of p27 could be due to increased SKP2 and in those cases targeting SKP2 would be
appropriate. However, decreased levels of p27 in tumor tissue may be unrelated to SKP2
expression, in which case inhibitors of SKP2 would likely have little effect on tumor
proliferation. Results from the TMX2-28 cell model demonstrate that SKP2-mediated
cell cycle entry is occurring in the presence of continued high levels of p27 and that
inhibition of SKP2 eliminates pSer10p27 and slows cell cycle while only modestly
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reducing p27. These results suggest that the combined high levels of SKP2 and
pSer10p27 may be a good indicator of whether inhibiting SKP2 will result in slowing cell
cycle and proliferation.
The relationship between SKP2 and pSer10p27 is a strong, but not perfect
correlation. SKP2 does not directly affect the phosphorylation of p27 at Ser10, thus, as
with the relationship between SKP2 and p27 the limited correlation could be due to other
factors that affect Ser10 phosphorylation, including but not limited to expression of
KIS/MIRK. However the strong relationship between SKP2 and pSer10p27 does suggest
that SKP2 is indirectly regulating this phosphorylation event.
The results from the present IHC analysis identified a subset of tumors with poor
prognosis and no available therapy, triple-negative tumors, which could respond to
inhibitors of SKP2. Agents that can specifically decrease SKP2 expression or activity
will provide a significant therapeutic impact and new, targeted therapeutic options for
patients who otherwise solely depend on the radiation and chemotherapy available to
them. Two studies have shown that the mTOR inhibitor rapamycin can also abrogate
SKP2’s actions by increasing degradation of SKP2 protein and interfering with its
transcription (112, 113). Additionally, one small molecule, Compound A, has been
shown to overcome chemotherapeutic resistance, specifically to dexamethasone,
doxorubicin and melphalan (114, 115). Compound A also inhibits cell growth via cell
cycle arrest in multiple myeloma cells by blocking recruitment of SKP2 to SCF
complexes (114). Another small molecule, SMIP0004 has been shown to decrease SKP2
expression in prostate cancer cells (115). Recently, a number of natural inhibitors of
SKP2 expression have been studied in breast cancer cell cultures. These compounds
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include curcumin, lycopene, pentagalloylglucose, quercetin, epigallocatechin-3-gallate
(EGCG), and gallic acid (116-118). However, further preclinical and clinical studies are
needed to verify the efficacy of these compounds.
The results of the present study provide additional and important information
about patients with triple-negative and basal-like breast cancers, and provide insight into
the importance of alterations in the cell cycle regulatory gene SKP2 on tumor
progression. Our findings suggest that SKP2 overexpression could modulate the
malignant phenotype of triple-negative and basal-like breast cancers, through regulation
of p27 phosphorylation. The precise molecular characterization of p27, direct and
indirect phosphorylation by SKP2 will be relevant to delineate the properties of these
breast cancer subtypes and identify patients with triple-negative and/or basal-like tumors
driven by SKP2 pathway dysregulation. These patients could possibly improve their
prognostic outcomes if treated with a targeted molecular therapy aiming to reduce
increased SKP2 levels by either small molecules and/or natural inhibitors.
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Table 2.1
Primers used to detect relative mRNA expression of genes
Gene
RefSeq
Forward Sequence Reverse Sequence
Number
(5'-3')
(5'-3')
SKP2

NM_005983

p27

NM_004064

CDK2

NM_001798

Cyclin E

NM_001238

Cyclin D1

NM_053056

HPRT

NM_000194

CATTTCAGCCCT GGGCAAATTCA
TTTCGTGT
GAGAATCCA
TGCAACCGACGA TTCCATGAAGT
TTCTTCTA
CAGCGATATGT
TTGTCAAGCTGC TGATGAGGGGA
TGGATGTC
AGAGGAATG
CCTGTACTGAGC CAAGCTCACCT
TGGGCAAA
CCATTAACCA
TGTGCCACAGAT CGGGTCACACT
GTGAAGTT
TGATCACTC
ACCCCACGAAGT AAGCAGATGGC
GTTGGATA
CACAGAACT
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Table 2.2
Clinical and pathological characteristics of patients
Characteristic
Age (in years)
Reduction Mammoplasty
All Tumors
ERα+
ERαNTN†
TN
N/A‡
Histology
DCIS
IDC
Other

Median (Range)

N (%)

25.5 (15-55)
55 (25-89)
55 (25-89)
54 (29-87)
58 (32-85)
53 (29-87)
59.5 (38-86)

40 (80)*
188 (100)
93 (49)
95 (51)
24 (25)
49 (52)
22 (23)
37 (20)
138 (73)
13 (7)

Tumor Grade
G1
23 (12)
G2
48 (26)
G3
105 (56)
N/A
12 (6)
*Age was not available for 10 reduction mammoplasty tissues;
†ERα-negative but either PR or HER2 positive; ‡ERα-negative
tumors that did not have HER2 status available
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Table 2.3
Expression of SKP2, p27, pSer10p27, Cyclin E, CDK2 and Cyclin D1 in breast tumors and
reduction mammoplasty (RM)
Positive
PHigh
Diffusea
PP-value
%( N)
value
% (N)
% (N)
value
SKP2
8
0
b
RM
(4 of 50)
(0 of 46)c
Tissue
<0.001
<0.001
Type
59
40
21
b
Cancer
(111 of 188)
(75 of 188)
(21of 98)
33
16
6
ERα+
(31of 93)
(15 of 93)
(2 of 31)
<0.001
<0.001
0.016
84
63
28
ERαHormone
b
(80 of 95)
(60 of 95)
(19 of 67)
Receptor
75
58
0
Status
NTNd
(18 of 24)
(14 of 24)
(0 of 14)b
0.002
0.056
0.003
98
80
40
e
TN
(48 of 49)
(39 of 49)
(19 of 48)
p27
79
21
4
RM
(23 of 29)
(6 of 290
(1 of 23)
Tissue
0.040
<0.001
<0.001
Type
92
69
61
Cancer
(146 0f 159)
(109 of 159)
(95 of 146)
93
69
71
ERα+
(78 of 84)
(58 of 84)
(55 of 78)
0.615
0.887
0.165
91
68
59
ERαHormone
(68 of 75)
(51 of 75)
(40 of 68)
Receptor
100
67
56
Status
NTNd
(18 of 18)
(12 of 18)
(10 of 18)
0.120
0.917
1.0
88
65
58
TNe
(43 of 49)
(32 of 49)
(25 of 43)
pSer10p27
24
12
12
RM
(8 of 33)
(4 of 33)
(1 of 8)
Tissue
0.006
0.015
0.427
Type
50
33
34
Cancer
(80 of 159)
(53 of 159)
(27 of 80)
36
15
33
ERα+
(30 of 84)
(13 of 84)
(10 of 30)
<0.001
<0.001
1.0
67
53
34
ERαHormone
(50 of 75)
(40 of 75)
(17 of 50)
Receptor
56
56
30
d
Status
NTN
(10 of 18)
(10 of 18)
(3 of 10)
0.372
0.856
0.711
67
53
36
TNe
(33 of 49)
(26 of 49)
(12 of 33)
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CDK2
0
(0 of 28)
<0.001
0.032
14
55
Cancer
(22 of 153)
(32 of 58)
22
71
ERα+
(18 of 82)
(27 of 38)
0.021
0.004
0.002
6
25
Hormone
ERα(4 of 71)
(5 of 20)
Receptor
0
14
Status
NTNd
(0 of 17)
(1 of 7)
0.208
0.291
0.603
6
33
TNe
(3 of 48)
(4 of 12)
Cyclin E
16
9
100
RM
(5 of 33)
(3 of 33)
(5 of 0)
Tissue
0.001
0.186
0.151
Type
49
19
58
Cancer
(77 of 154)
(30 of 157)
(45 of 77)
46
12
72
ERα+
(39 of 84)
(10 of 84)
(28 of 39)
0.482
0.014
0.021
52
27
45
ERαHormone
(38 of 73)
(20 of 73)
(17 of 38)
Receptor
41
24
40
d
Status
NTN
(7 of 17)
(4 of 17)
(4 of 10)
0.579
0.688
0.723
51
29
48
TNe
(25 of 49)
(14 of 49)
(12 of 25)
Cyclin D1
0
0
RM
Tissue
(0 of 40)
(0 of 40)
<0.001
<0.001
Type
80
61
30
Cancer
(127 of 158)
(97 of 158)
(38 of 127)
92
70
40
ERα+
(77 of 84)
(59 of 84)
(31 of 77)
<0.001
0.015
0.002
68
51
14
Hormone
ERα(50 of 74)
(38 of 74)
(7 of 50)
Receptor
82
71
14
Status
NTNd
(14 of 17)
(12 of 17)
(2 of 14)
0.084
0.024
1.0
59
39
14
e
TN
(29 of 49)
(19 of 49)
(4 of 29)
a
Diffuse and Focal staining was evaluated only for tissues that scored positive
b
Thirteen tumors and 4 RM tissues with SKP2 reactivity were not evaluated for distribution of
staining, therefore the numbers for diffuse and focal are reduced
c
Four RM tissues were scored as positive/negative only, therefore the numbers for high/low are
reduced
d
NTN: Non-triple-negative, tumors that were negative for ERα, but positive for PR and/or HER2
receptors
e
TN: Triple-negative, tumors that were negative for ERα, PR and HER2 receptors
Tissue
Type

RM

0
(0 of 28)
38
(58 of 153)
46
(38 of 82)
28
(20 of 71)
59
(10 of 17)
25
(12 of 48)
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Table 2.4
Relationship between SKP2 expression in breast cancer and cell cycle genes
SKP2 Expression
SKP2 Expression
% (N)
% (N)
Positive

Negative

PValue

High

Low

PValue

Cell Cycle
Cell Cycle
Gene
Gene
p27
94
89
p27
74
64
0.231
0.202
Positive
(92 of 98) (54 of 61)
Positive
(51 of 69) (58 of 90)
pSer10p27
67
23
pSer10p27
55
17
<0.001
<0.001
Positive
(66 of 98) (14 of 61)
Positive
(38 of 69) (15 of 90)
CDK2
35
42
CDK2
7
20
0.367
0.031
Positive
(33 of 94) (25 of 59)
Positive
(5 of 67) (17 of 86)
Cyclin E
56
40
Cyclin E
26
13
0.035
0.040
Positive
(54 of 97) (23 of 57)
Positive
(18 of 68) (12 of 89)
Cyclin D1
78
84
Cyclin D1
65
59
0.418
0.457
Positive
(76 of 97) (51 of 61)
Positive
(44 of 68) (53 of 90)
p-values reflect results of χ2 testing the relationship between expression of SKP2 and one other
cell cycle gene
Note: The percentages (and numbers) provided are based on the positive and high expression
of specific cell cycle genes in tumors when SKP2 was evaluated as positive/negative and as
high/low.
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Table 2.5
Relationship between strong protein expression and age
Relationship
N (P-value)
SKP2
Total tumors
Inverse
159 (0.005)
ERα+
84 (0.261)
ERαInverse
75 (0.014)
NTN
18 (0.835)
TN
Inverse
49 (0.029)
p27
Total tumors
159 (0.530)
ERα+
84 (0.929)
ERα75 (0.440)
NTN
Positive
18 (0.018)
TN
49 (0.219)
pSer10p27
Total tumors
Positive
159 (0.003)
ERα+
84 (0.237)
ERαPositive
75 (0.004)
NTN
Positive
18 (0.021)
TN
Positive
49 (0.020)
CDK2
Total tumors
Positive
153 (0.212)
ERα+
82 (0.759)
ERαPositive
71 (0.032)
NTN
*
TN
48 (0.103)
Cyclin E
Total tumors
157 (0.640)
ERα+
*
ERα73 (0.612)
NTN
*
TN
49 (0.471)
Cyclin D1
Total tumors
Positive
158 (0.012)
ERα+
84 (0.389)
ERαPositive
74 (0.006)
NTN
17 (0.726)
TN
Positive
49 (0.017)
* Relationship could not be established due to zero tumors
with strong positive staining.
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Table 2.6
Relationship between strong protein expression and tumor type
Cell Cycle
DCIS
IDC
P-value
Gene
% (N)
% (N)
SKP2
3 (1 of 37)
19 (26 of 138)
<0.001
p27
38 (14 of 37)
33 (36 of 109)
0.955
pSer10p27
11 (4 of 37)
17 (19 of 109)
0.467
CDK2
27 (9 of 33)
1 (1 of 107)
<0.001
Cyclin E
0 (0 of 36)
1 (1 of 108)
0.106
Cyclin D1
27 (10 of 37)
30 (32 of 108)
0.009
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Table 2.7
Relationship between strong protein expression and tumor grade
Cell Cycle
Grade 1
Grade 2
Grade 3
Gene
% (N)
% (N)
% (N)
SKP2
0 (0 of 23)
10 (5 of 48)
26 (27 of 105)
p27
3 (6 of 20)
28 (11 of 40)
37 (32 of 87)
pSer10p27
10 (2 of 20)
8 (3 of 40)
21 (18 of 87)
CDK2
5 (1 of 19)
10 (4 of 40)
5 (4 of 85)
Cyclin E
0 (0 of 20)
3 (1 of 40)
1 (1 of 86)
Cyclin D1
25 (5 of 20)
38 (15 of 40)
26 (23 of 87)
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P-value
0.004
0.690
0.177
0.454
0.702
0.298
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(Figure 2.1)
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(Figure 2.1)
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Figure 2.1 TMX2-28 is a triple-negative derivative of the MCF-7 breast cancer cell line.
Upper panel: Relative mRNA expression of (A) ERα, (B) PR, and (C) HER2 were
determined by real time qRT-PCR and normalized to HPRT. Differences among cell
lines were analyzed with one-way ANOVA and post hoc t-tests with Bonferroni
correction; *p<0.05, ***p<0.001; Panel A & B: MCF-7 differed significantly from all
other cell lines Panel C: SKBR-3 differed significantly from all other cell lines. Lower
panel: ERα, PR, and HER2 protein expression was determined by
immunohistochemistry.
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(Figure 2.2)
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Figure 2.2 SKP2 is overexpressed in TMX2-28 cells. (A) Relative SKP2 mRNA
expression in TMX2-28, MCF-7, and MDA-MB-231 cells was determined by real time
qRT-PCR. SKP2 protein expression was determined by Western immunoblotting
(GAPDH as loading control). (B) TMX2-28 cells were stably transfected with either a
negative control pGIPZ shRNAmir (TMX2-28-NC), or a pGIPZ shRNAmir targeted
against SKP2 (TMX2-28-S2, TMX2-28-MC). Relative SKP2 mRNA and protein
expression was determined as in panel A. Differences in mRNA levels among cell lines
were analyzed using one-way ANOVA and post hoc t-tests with a Bonferroni correction
(*p<0.05; **p<0.01); Panel A: TMX2-28 differed significantly from other cell lines;
Panel B: TMX2-28 and TMX2-28-NC differed significantly from other groups but not
from each other.
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Figure 2.3 Expression of SKP2 pathway genes in TMX2-28 cells. Relative mRNA
expression of (A) p27, (B) Cyclin E, (C) CDK2, and (D) Cyclin D1 were determined by
real time qRT-PCR and normalized to HPRT. Protein expression of (A) p27, (B) Cyclin
E, (C) CDK2, and (D) Cyclin D1 were determined by Western immunoblotting (GAPDH
as loading control). Differences in mRNA levels among cell lines were analyzed using
one-way ANOVA and post hoc t-tests with a Bonferroni correction for comparisons
between TMX2-28 cells and MCF-7 cells †p<0.005; for comparisons between TMX2-28
cells and MDA-MB-231 cells ‡p<0.05; for comparisons between TMX2-28-NC and
TMX2-28-S2 or TMX2-28-MC cells **p<0.01, ***p<0.001.
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Figure 2.4 SKP2 knockdown decreased the percentage of cells in the S-phase of the cell
cycle. TMX2-28-NC, TMX2-28-S2, and TMX2-28-MC cells were fixed and stained
with propidium iodide. Cell cycle analysis was assessed by flow cytometry (*p<0.05;
**p<0.01).
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Frozen Breast Carcinoma Specimens
Figure 2.5 SKP2 is overexpressed in ERα-negative, basal-like breast tumors. Relative
SKP2 mRNA expression was determined in 30 frozen breast carcinoma samples using
real time qRT-PCR normalized to HPRT. Numbers 1-18 indicates ERα-positive tumors,
while ERα-negative tumors were assigned numbers 19-30. ERα-positive tumors that had
CK 5 and/or CK17 positivity were classified as basal-cytokeratin-expressing tumors and
are represented by striped bars. ERα-negative tumors that also had expression of CK 5
and/or 17 were termed basal-like and are represented by black bars.
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Negative

Weak

Moderate

Strong

Figure 2.6 Scoring system used to evaluate cell cycle proteins in human tissue. Intensity
of immunoreactivity of epithelial cells was used to assign scores of negative, weak,
moderate, and strong staining. Images are from tumor samples with insets show
increasing intensity of protein staining. Scale bar = 100 µm.
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Figure 2.7 Expression of SKP2 in breast cancer tumors is highly correlated with
pSer10p27 (Case 1). Breast tumors TMAs and tissue slides were prepared, stained, and
scored as described in the Methods. Representative images of tumor tissue show the
relationships between the expression of SKP2, p27, pSer10p27, CDK2, Cyclin E, and
Cyclin D1 when SKP2 expression is high. Scale bar =100 µm.
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Figure 2.8 Expression of SKP2 in breast cancer tumors is highly correlated with
pSer10p27 (Case 2). Breast tumors TMAs and tissue slides were prepared, stained, and
scored as described in the Methods. Representative images of tumor tissue show the
relationships between the expression of SKP2, p27, pSer10p27, CDK2, Cyclin E, and
Cyclin D1 when SKP2 expression is high. Scale bar =100 µm.
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Figure 2.9 Expression of SKP2 in breast cancer tumors is highly correlated with
pSer10p27 (Case 3). Breast tumors TMAs and tissue slides were prepared, stained, and
scored as described in the Methods. Representative images of tumor tissue show the
relationships between the expression of SKP2, p27, pSer10p27, CDK2, Cyclin E, and
Cyclin D1 when SKP2 expression low. Scale bar =100 µm.
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Figure 2.10 Expression of SKP2 in breast cancer tumors is highly correlated with
pSer10p27 (Case 4). Breast tumors and RM TMAs and tissue slides were prepared,
stained, and scored as described in the Methods. Representative images of tumor tissue
show the relationships between the expression of SKP2, p27, pSer10p27, CDK2, Cyclin
E, and Cyclin D1 when SKP2 expression low. Scale bar =100 µm.
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CHAPTER 3

THE RAS HOMOLOG GENE FAMILY, MEMBER A (RHOA) PATHWAY
MEDIATES PROTEASE-INDEPENDENT INVASIVE BEHAVIOR IN A
TRIPLE-NEGATIVE BREAST CANCER CELL LINE

Introduction
Metastasis is dependent upon cancer cells being able to invade surrounding extra
cellular matrix (ECM) and adapt to different microenvironments within the primary
tumor, the ECM, blood and/or lymphatic systems, and finally, to establish a new niche in
a distant tissue (41-43). The proteins that control cell-cell and ECM interactions are
thought to play a role in tumor cell invasion and metastasis by controlling cell
morphology, motility, and interactions with the tumor microenvironment (41, 44). Thus,
such proteins provide attractive therapeutic targets.
Two distinct morphological/functional mechanisms are known for single cell
migration in tissues: fibroblast-type mesenchymal invasion, and leucocyte-type amoeboid
invasion. Mesenchymal movement is characterized by an elongated cellular shape, and
involves the use of proteases that cause cellular lysis in tissues, thereby creating a path
through which cells can invade (44-47). Amoeboid migrating cells have a rounded
morphology and their movement is protease–independent. Instead, cells find paths
through the ECM by pushing and squeezing through regions of adequate size (43, 44, 47,
51, 52).
Matrix Metalloproteinases (MMPs) are a family of endopeptidases capable of
degrading ECM components. MMPs are synthesized and secreted as zinc dependent
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proenzymes that require activation prior to becoming proteolytically active (119). It is
known that MMP-1, MMP-2, and MMP-9 are responsible for degrading fibrillar collagen
as well as collagen type IV, the primary components of the connective tissue matrix and
basement membranes respectively (120-122). A number of studies have shown that there
is an association between high MMP-2 and MMP-9 expression and the invasiveness of
tumors when compared to normal breast epithelium. Cells undergoing epithelial to
mesenchymal transition (EMT) in particular have high expression of MMP-2 and MMP-9
(123-128).
Migration of cancer cells is dependent on Ras Homolog Gene Family, Member A
(RhoA) signaling (43, 44, 47, 51, 52). RhoA is a member of the Rho superfamily of
GTPases that acts as a molecular switch to control signal transduction (55). It carries out
its actions through activation of its two targets: Rho-associated, coiled-coil containing
protein kinase (ROCK) 1 and ROCK 2, which in turn regulate different facets of actin
dynamics including stress fiber assembly, cell contraction, actin-filament stabilization,
and focal adhesion organization (56-59). Up-regulation of RhoA mRNA and protein is
well documented for a variety of human cancers and has been positively correlated with
cancer metastasis (64-66).
In this study, we use the Tamoxifen-selected, MCF-7 derivative, TMX2-28 breast
cancer cell line. TMX2-28 cells are triple-negative (Figure 2.1) and have acquired a
mixed basal/luminal cytokeratin profile, suggestive of a more basal-like phenotype (6769). Morphologically, TMX2-28 cells retained an epithelial cell shape similar to MCF-7.
Behaviorally, TMX2-28 cells are highly invasive, as assessed through the ability to
invade though Matrigel, when compared to MCF-7 and MDA-MB-231 breast cancer
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cells (67). These phenotypic characteristics suggest that these cells may exhibit an
amoeboid mode of invasion. However, the importance of matrix metalloproteinases
(MMPs) in invasion was not experimentally excluded nor was evidence of amoeboid
invasion by these cells demonstrated.
A cDNA microarray comparing gene expression of TMX2-28 cells to their parent
cell line, MCF-7, indicated that the Rho family member, RhoE is downregulated in
TMX2-28 (Table 3.1). RhoE was the first member of the Rho kinase family to be
identified (129). Unlike the other family members, RhoE does not act as a classic
GTPase switch, as it does not hydrolyze GTP (129-131). RhoE functions by binding to
and inhibiting the RhoA effector ROCK 1 (but not ROCK 2). This interaction also
results in the phosphorylation of RhoE by ROCK 1, which increases RhoE’s stability and
activity (73, 132). In addition, RhoE binds to p190RhoGAP and increases its activity
toward RhoA, thus promoting the formation of inactive GDP-bound RhoA (133). This
data led to the question, since TMX2-28 cells downregulate the expression of RhoA
inhibitor RhoE, do TMX2-28 upregulated RhoA, and if so, is the upregulation of RhoA
resulting in the increased invasiveness of these cells? In the present study we seek to
further define the molecular aspects underlying their invasive mechanism.

Materials and Methods
Cell Culture: TMX2-28, MCF-7, and HeLa cells were maintained in T-75 culture
flasks at 37°C and 5% CO2, in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with calf serum (5%), insulin (10 µg/ml), non-essential amino acids
(100X), penicillin-streptomycin (10,000 µg/ml), and L-glutamine (200 mM). MDA-MB-
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231 cells were maintained in Leibovitz-15 (L-15) medium supplemented with 10% FBS
at 37°C and 0% CO2. All cells were passaged when near 80% confluence.

RNA and Protein Isolation: Total RNA (n=3 biological samples) was isolated
with Tri-Reagent (Molecular Research Center, Cincinnati, OH) according to
manufacturer’s suggestions and protocols as previously described (67, 68, 101). RNA
was then treated with Turbo DNA-Free (Ambion, Austin, TX) to remove any DNA
contamination. The quality of the RNA was assessed by 260/280 nm spectrophotometer
readings (Nanodrop 8000; Thermo Scientific, Wilmington, DE). Protein- containing cell
lysates were isolated from cell cultures (n=3 biological samples) with pre-chilled SDS
lysis buffer (1% SDS, 0.06 M Tris-HCL, and 10% glycerol) according to our standard
laboratory protocols (67, 68, 101). Extracts were used for Western immunoblotting.

Western Immunoblotting: Protein lysates were mixed with NuPage sample
buffer and reducing agent (Invitrogen, Carlsbad, CA), heated at 70°C for 10 min,
separated on a Mini-PROTEAN TGX gels (Bio-Rad, Hercules, CA) and then transferred
to an Immuno-Blot polyvinylidene difluoride membrane (Bio-Rad, Hercules, CA)
according to manufacturer’s protocols. Membranes were incubated in blocking buffer
(5% nonfat dry milk/Tris buffered saline and 0.1% Tween 20) for 1 hour at room
temperature with gentle shaking. Membranes were then incubated with anti-RhoA rabbit
monoclonal antibody (Cell Signaling Technology, Danvers, MA) diluted 1:1000
overnight at 4°C, followed by incubation with the secondary antibody, anti-rabbit IgG
linked to horseradish peroxidase; diluted 1:1000 (Cell Signaling Technology, Danvers,
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MA), for 1 hour at room temperature. Chemiluminescent signals were detected with
SuperSignal West Pico Kit and protocol (Peirce, Rockford, IL), and imaged using the
G.BOX Chemi HR-16 (Syngene, Fredrick, MD). Membranes were stripped using
Restore stripping buffer (Thermo Scientific, Rockford, IL) and reprobed for
gleceraldehyde-3-phosphate (Cell Signaling Technology, Danvers, MA; 1:10,000).

Quantitative Real Time Reverse Transcriptase PCR (qRT-PCR): RNA samples
(n=3 biological samples) were reverse transcribed and amplified using the One Step RTPCR kit (Qiagen, Valencia, CA) in the Roche LightCycler (Roche, Indianapolis, IN).
Total RNA (75 ng) was incubated with Qiagen RT-PCR master mix including primers
(25µM each) and SYBR Green I nucleic acid stain (2X; Invitrogen, Carlsbad, CA,
product number S7563) in pre-cooled capillaries (Roche, Indianapolis, IN) and was
reversed transcribed (50°C for 30 min). Following reverse transcription, samples were
heated to 95°C for 15 min to activate the HotStar Taq DNA polymerase and to
simultaneously inactivate the reverse transcriptase. The generation of amplified products
was monitored over 45 PCR cycles by fluorescence of intercalating SYBR Green. Each
cycle consisted of the following steps: 1. Denaturation at 95°C for 15 sec. 2. Annealing
at 60°C for 15 sec. 3. Extension at 72°C for 30 sec. Relative mRNA levels were
normalized to hypoxanthine ribosyltransferase (HPRT) levels to control for RNA quality
and concentration. Gene specific primers, designed using Primer3 software
(http://frodo.wi.mit.edu/), and purchased from Integrated DNA Technologies, Inc.
(Coralville, IA), were used for MMP-1, MMP-2, MMP-9, SLUG, ZEB 1, ZEB 2,
Vimentin, Fibronectin, N-Cadherin, RhoA, ROCK 1, ROCK 2, and HPRT (Table 3.2).

78

Matrigel Invasion Assay: BD BioCoat Matrigel Invasion Chambers and 8.0 µm
pore size PET track-etched membranes (Becton Dickinson, Franklin Lakes, NJ) were
used according to the manufacturer’s protocol. Cells (5 x 104 cells total; n=3 biological
samples) were plated in the top chamber containing a basal medium (DMEM). A
medium rich in nutrients (DMEM supplemented with 10% FBS) was used in the bottom
chamber as a chemoattractant. Twenty-two to twenty-four hours later, cells were fixed
and stained using 10% formalin and crystal violet respectively. Cell numbers were
determined from microphotographs taken over four (non-overlapping) areas of the
membrane.

Zymography: Gelatin zymography was performed using precast polyacrylamide
gels containing 10% gelatin (Bio-Rad, Hercules, CA). Collected serum free, conditioned
medium (n=3 biological samples) was mixed in equal volumes with sample buffer (0.5 M
Tris-HCL, glycerol, 10% SDS, 0.1% Bromophenol blue). To prepare serum free
conditioned medium, cells were seeded into 24-well tissue culture plates at a
concentration of 1x105 cells/well in normal culture medium. Twenty-four hours post
seeding, cells were washed three times with phosphate-buffered saline followed by
incubation in serum free medium. Serum free conditioned medium was collected 48
hours later and stored at -20°C until use. Twenty to fifty microliters of mixed sample
was loaded into the gel and electrophoresed at 100 V for 90 min. Following
electrophoresis, gels were rinsed with 1X renaturing buffer (2.5% Triton X-100) for 30
min with gentle agitation. Gels were then transferred to 1X developing buffer (50 mM
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Tris base, 200 mM NaCL, 5 mM CaCl2, 0.02% Brij 35) for 30 min at room temperature
with gentle agitation to equilibrate the gel. Gels were then incubated overnight at 37°C
with gentle agitation in fresh 1X developing buffer. Gels were then stained for 1 hour
with 0.5% Coomassie Blue, de-stained twice for 30 min each with de-staining solution
[Methanol: Acetic Acid: Water (50:10:40)], and rehydrated in H2O for 10 min.

Inhibitor and siRNA Treatments: For inhibitor assays, cells (n=3 biological
samples) were treated with the Rho Kinase pathway inhibitor H-1152 (Calbiochem,
Billerica, MA) at 0, 20, and 100 µM concentrations for 24 hours (134, 135).
Concentrations were determined by dose response testing (See Appendix B). Following
treatment, either RNA was isolated as mentioned above, or cells were seeded into
invasion chambers in the respective concentrations of inhibitor.
For siRNA assays, RhoA specific and negative control (random sequence without
homology to any human gene) siRNAs (RhoA-siRNA and NC-siRNA respectively) were
designed using Ambion’s (Austin, TX) siRNA Template Design Tool (RhoA sense:
CCUUAUAGUUACUGUGUAATT; antisense: UUACACAGUAACUAUAAAGGTA;
negative control sense: UUAUCGCCAAAUUCUUUUAUCGGACAGAG; antisense:
UUGAUAAAAGAAUUUGGCGAUGGACAGAG). DNA oligonucleotides were
purchased from Integrated DNA Technologies, Inc. (Coralville, IA) and siRNA generated
using Silencer® siRNA Construction Kit (Ambion, Austin, TX) per manufactures’
protocols. TMX2-28, MCF-7 (non-invasive control) and HeLa (RhoA dependent
invasion control) cells were seeded into 100 mm dishes at a concentration of 106
cells/dish and allowed to attach overnight (n=3 biological samples). On the day of
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transfection, HiPerFect transfection agent (Qiagen, Valencia, CA) and 25 mg/well of a
RhoA specific or a negative control siRNA was diluted into Opti-MEM (Invitorgen,
Carlsbad, CA) and added to cells. Following incubation under normal growth conditions
for 48 hours, cells were harvested for both RNA and Protein isolation or invasion assays.

Statistical Analyses: Data were analyzed and graphed with GraphPad Prism
Version 3.02 (GraphPad Software, Inc., San Diego, CA). For ANOVA and post hoc
comparisons, significance was set at p<0.05.

Results
TMX2-28 cells do not express MMP-1 mRNA or active MMP-2 or MMP-9 protein
In breast cancer, MMPs have been shown to be important players in mesenchymal
invasion, specifically MMP-1, -2, and -9 (120-122, 136). To determine the possible
involvement of MMPs in the invasion mechanism of TMX2-28 cells, MMP-1, -2, and -9
mRNA expression was analyzed by qRT-PCR. As shown in Figure 3.1 A-C, TMX2-28
cells have significantly lower MMP-1 mRNA expression (no detectable level) when
compared to the mesenchymal MDA-MB-231 cells. However, there was no significant
difference in mRNA expression of MMP-2 or MMP-9 among the cell lines. MMPs are
synthesized and secreted as zinc dependent pro-enzymes that require activation (119). To
assess activity of MMP-2 and -9, conditioned media from all cell lines were run on a
zymography gel. It was determined that although TMX2-28 cells have mRNA
expression, they do not express active MMP-2 or MMP-9 enzymes (Figure 3.1 D). These
results indicate that TMX2-28 cells do not rely on MMP activity to degrade the ECM.
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TMX2-28 cells have little to no expression of six common EMT genes
Epithelial-mesenchymal transition (EMT) is a well-recognized process facilitating
migration and invasion of cancer cells during metastasis (137). An increase in expression
of a number of genes including SLUG, ZEB1, ZEB2, Fibronectin, Vimentin, and NCadherin is characteristic of this process (138-143). The mRNA levels of these genes
were assessed by qRT-PCR to determine whether TMX2-28 cells have increased
expression. Gene expression of SLUG, ZEB1, ZEB2, Fibronectin and Vimentin, was
found to be low in TMX2-28 cell cultures (Table 3.3), similar to that in the non-invasive
parent cell line, MCF-7. The expression of all six genes was significantly higher in the
invasive, mesenchymal-like MDA-MB-231 cell line than in either the non-invasive
MCF-7 or the invasive TMX2-28 cells. While expression of N-Cadherin in TMX2-28
was slightly above that in MCF-7 cells, it was still significantly less than in MDA-MB231 cells. Together with results on MMP expression, these data suggest that TMX2-28
cells do not utilize the protease-dependent, mesenchymal invasion mechanism.

RhoA pathway genes are overexpressed in TMX2-28 cells
Next, we questioned whether TMX2-28 cells exploit the Rho kinase pathway,
specifically RhoA pathway signaling. RhoA mRNA was overexpressed in TMX2-28
cells at both the mRNA and protein levels (Figure 3.2 A) when compared to levels in
MCF-7 and MDA-MB-231 cells. Additionally, the major downstream targets of RhoA,
ROCK 1 and ROCK 2, were also found to be overexpressed in these cells (Figure 3.2 B
and C). These data suggest that TMX2-28 cells may take advantage of RhoA dependent,
protease-independent invasion process.
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Blocking RhoA pathway activity decreased migratory and invasive behaviors

We next designed experiments to determine whether blocking the activity of
RhoA resulted in impairment of migratory and invasive behavior. For these studies,
TMX2-28 cells were treated with the ROCK inhibitor H-1152 to block RhoA pathway
signaling. HeLa (RhoA dependent invasion control), and MCF-7 (non-invasive control)
cells were also used as positive and negative controls respectively. As expected,
blocking RhoA activity in the RhoA dependent HeLa cells resulted in significant
abrogation (~66%) of invasive behavior. When RhoA activity was blocked in TMX2-28
cells, there was significant inhibition of migration and invasion (Figure 3.3). Migration
was reduced by ~90% and ~94% when cells were treated with 20 and 100 µM of the
inhibitor respectively. In contrast, the reduction of invasion was dose-dependent, ~62%
inhibition after treatment with 20 µM and ~92% inhibition after treatment with 100 µM.
To further investigate the effect of blocking RhoA signaling on migration and
invasion, siRNA specifically targeting RhoA was used to knockdown expression in
TMX2-28, MCF-7 and HeLa cells (Figure 3.4 A). Knockdown of RhoA in these cells
resulted in a significant decrease in both migratory (50%) and invasive (52%) behavior
(Figure 3.4 B), confirming the phenotypic changes observed when RhoA pathway
signaling was blocked using H-1152 (Figure 3.3). This effect was specific and was not
seen when cells were transfected with the negative control siRNA. Together these data
show that RhoA plays an important role in the ability of TMX2-28 cells to be highly
invasive and migratory while maintaining an epithelial morphology.

83

Discussion
Cancer cells can use alternative mechanisms of motility for invasion (45, 47).
Two distinct mechanisms have been identified, the more widely utilized, proteasedependent, mesenchymal, and the less utilized, protease-independent, amoeboid
movements (44-47). In breast cancer, MMPs have been tied to mesenchymal cell
movement (128), however blocking MMP activity was unsuccessful in preventing growth
and metastasis of late stage cancers in clinical trials (46, 144). Additionally, a study by
Wolf and colleagues showed that when triple-negative, mesenchymal, MDA-MB-231
breast cancer cells were challenged with MMP inhibitors, these cells adapted a round,
epithelial-like morphology and continued to be invasive (47). These studies suggest that
breast cancer cells have the ability to utilize an amoeboid invasion mechanism. Thus,
determining the mechanisms behind this mode of invasion is critical for the development
of therapies to block the metastatic process.
The primary objective of the present study was to better define the molecular
aspects underlying invasion, in TMX2-28 cells as a model of triple-negative, basal-like
breast cancer. We previously reported that the Tamoxifen-selected derivative of MCF-7
cells, TMX2-28, are ERα negative and highly invasive (67-69); comparable to MDAMB-231 cells, an established breast cancer cell line known for being highly invasive and
exploiting the proteolytic-dependent, mesenchymal mode of invasion. The rounded,
epithelial-like cell morphology of TMX2-28 cells suggests an amoeboid mode of cellular
invasion, however, this was not investigated.
The Tamoxifen-selected, MCF-7 derived TMX2-28 cells were used as a model to
study migration and invasion in triple-negative, basal-like breast cancer. Previous studies
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of gene expression and IHC identified TMX2-28 cells as triple-negative (Chapter 2) and
having a mixed basal/luminal CK expression profile (Chapter 4) (68). In the present
paper, our initial inquiry focused on experimentally excluding proteolytic pathways in
TMX2-28 invasion. We determined that TMX2-28 cells do not express MMP-1 mRNA
or active MMP-2 or -9 protein, nor do they have expression of genes known to increase
in expression during EMT. Interestingly, a cDNA microarray comparing gene expression
of TMX2-28 cells to their parent cell line, MCF-7, indicated that a number of proteases,
MMPs, and adhesion molecules are downregulated in TMX2-28 (Table 3.1) (67, 68).
These data together with the lack of MMP-1, -2, or -9 or EMT gene expression indicate
that proteases are not critical to TMX2-28’s invasion mechanism and thus they do not
utilize a mesenchymal migration mechanism.
The next logical research direction we took was to determine which pathway
TMX2-28 cells use to migrate. cDNA microarray analysis indicated the TMX2-28 cells
downregulate the RhoE, which acts as an inhibitor of RhoA (133). It is known that RhoA
signaling is important for many types of migration, and up-regulation of RhoA in cancer
has been associated with cancer metastasis (45, 46, 64-66). It was found that TMX2-28
cells overexpress RhoA mRNA and protein. Additionally, they overexpress mRNA from
RhoA’s two main targets ROCK 1 and 2. This provides three potential targets for
therapy development against metastasis. Furthermore, inhibition of RhoA pathway
activity through the use of either the ROCK inhibitor H-1152, or a RhoA specific siRNA
resulted in decreased migratory and invasive behavior.
Based on these observations, we can conclude that TMX2-28 cells do not use
protease dependent mesenchymal movements as their primary invasion mechanism. Their
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rounded morphology, use of RhoA, and lack of mesenchymal phenotype, supports our
hypothesis that TMX2-28 use amoeboid movement. Furthermore, the cDNA microarray
mentioned previously, also revealed that TMX2-28 cells expressed mRNA for a number
of genes known to regulate cell membrane morphology and control cytoskeletal
organization (Table 3.1). These included mitogen inducible gene 2 (MIG2). MIG2 is a
component of cell-ECM adhesion sites that control cell shape and spreading. MIG2
promotes cellular dynamics though the recruitment of Migfilin and its interactions with
Filamin and actin (67, 145, 146). A study by Gozgit et. al. showed that MIG2 is
overexpressed in TMX2-28 cells as well as in breast cancer tissues (67). Knockdown of
MIG2 also resulted in reduced invasive behavior. RhoA signaling is known to be
involved in focal adhesion formation along with MIG2 (145, 147, 148). From this
knowledge one could suggest that RhoA and MIG2 may work collectively to facilitate
amoeboid invasion. Further investigation into how these two proteins may interact is
necessary for complete understanding of this mechanism.
An understanding of the mechanisms behind cell migration and tumor metastasis
is critical given that metastasis accounts for the majority of breast cancer deaths.
Collectively, the results of our study suggest that TMX2-28 cells exploit a RhoA
dependent, proteolytic-independent invasion mechanism. Targeting the RhoA pathway in
triple-negative, basal-like breast cancer cells that have a proteolytic-independent invasion
mechanism may provide therapeutic strategies for the treatment of cancer patients with
increased risk of metastasis.
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Table 3.1
Genes associated with cytoskeleton organization, protease secretion, adhesion, and
membrane morphology differentially regulated in TMX2-28 as compared with
MCF-7
Gene Symbol
Accession
Gene Name
Number
ADAM metallopeptidase with
thrombospondin type 1 motif

ADAMTS19

NM_133638.1

Matrix metallopeptidase-like 1
(Matrix metallopeptidase 25)

MMPL1
(MMP25)

NM_004142.1

Protease, Serine, 23

NM_007173.1

TIMP metallopeptidase inhibitor 1
TIMP metallopeptidase inhibitor 2

SPUVE
(PRSS23)
TIMP1
TIMP2

Neuronal cell adhesion molecule

NRCAM

NM_005010.1

Fibronectin leucine rich
transmembrane protein 3
Fibroblast growth factor 13

FLRT3

NM_013281.1

FGF13

NM_004114.1

Selectin L

SELL

NM_000655.2

Ras homolog gene family, member E

RHOE

NM_001254738.1

EGF-containing fibulin-like
extracellular matrix protein 1
Carcinoembryonic antigen-related
cell adhesion molecule 5

EFEMP1

NM_004105.2

CEACAM5

NM_004363.1

Cathespin D
Cathepsin F
Cathepsin S
Integrin β8

CTSD
CTSF
CTSS
ITGB8

NM_001909.4
NM_003793.3
NM_001199739.1
NM_002214.2

Integrin α6
Laminin, gamma 1
Laminin, beta 1
Vitronectin

ITGA6
LAMC1
LAMB1
VTN

NM_000210.1
NM_002293.3
NM_002291.1
NM_000638.1

Serpin peptidase inhibitor, clade E
member 1

SERPINE1

NM_000602.3

Mitogen inducible gene 2

MIG2

NM_006832

NM_003254.1
NM_003255.2
DOWNREGULATED
UPREGULATED

http://www.nature.com/bjc/journal/v97/n6/suppinfo/6603926s1.html?url=/bjc/journal/v9
7/n6/full/6603926a.html; (68)
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Table 3.2
Primers used to detect relative mRNA expression of genes
Gene
RefSeq Number
Forward Sequence
(5'-3')
ATGATCAACTGGG
ERα
NM_000125
CGAAGAG
GGAAGGGCTACGA
PR
NM_000926.4
AGTCAAA
CCCCAGCCTGAAT
HER2
M11730
ATGTGAA
CGACTCTAGAAAC
MMP-1
NM_002421
ACAAGAGCAAGA
GTGCTGAAGGACA
MMP-2
NM_004530
CACTAAAGAAGA
CACTGTCCACCCC
MMP-9
NM_004994
TCAGAGC
CATGCCTGTCATA
SLUG
NM_003068.4
CCACAAC
GGGAGGAGCAGTG
ZEB 1
NM_001128128.2
AAAGAGA
AAGCCAGGGACAG
ZEB 2
NM_014795.3
ATCAGC
AAAGTGTGGCTGC
Vimentin
NM_003380.3
CAAGAAC
GAACTATGATGCC
Fibronectin
NM_212482.1
GACCAGAA
CACTGCTCAGGAC
N-Cadherin
NM_001792.3
CCAGAT
GATGGAAAGCAGG
RhoA
NM_001664
TAGAGTTGG
AATGCTTGTAGGT
ROCK 1
NM_005406
GATACACCTTTT
GAAGTGCAGTTGG
ROCK 2
NM_004850
TTCGTCA
ACCCCACGAAGTG
HPRT
NM_000194
TTGGATA
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Reverse Sequence
(5'-3')
GATCTCCACCATG
CCCTCTA
TAACTTGCATGAT
CTTGTCAAACA
CTCTGGGTTCTCTG
CCGTAG
AAGGTTAGCTTAC
TGTCACACGCTT
TTGCCATCCTTCTC
AAAGTTGTAGG
GCCACTTGTCGGC
GATAAGG
GGTGTCAGATGGA
GGAGGG
TTTCTTGCCCTTCC
TTTCTG
CCACACTCTGTGC
ATTTGAACT
AGCCTCAGAGAGG
TCAGCAA
GGTTGTGCAGATT
TCCTCGT
TAGCCGAGGATGG
TCC
TCAGTATAACATC
GGTATCTGGGTA
CTGTCAGTAAGGA
AGGCACAAA
GCTATTGGCAAAG
GCCATAA
AAGCAGATGGCCA
CAGAACT

Table 3.3
Relative mRNA expression of epithelial to mesenchymal genes in cell lines
Target
TMX2-28
MCF-7
MDA-MB-231
-4 **
SLUG
0.0039 ± 8.8 x10
0.0060 ± 0.002
1.8748 ± 0.464
**
ZEB1
0.0336 ± 0.008
0.0098 ± 0.003
0.5865 ± 0.158
ZEB2
0.0009 ± 3.7 x 10-4 *** 0.0013 ± 6.1 x 10-4 0.2202 ± 0.041
Fibronectin
0.0090 ± 0.004§*
1.1013 ± 0.364
0.7001 ± 0.042
-5 **
-4
Vimentin
0.0005 ± 3.7 x 10
0.0005 ± 1.2 x 10
0.5461 ± 0.139
N-Cadherin
0.6086 ± 0.282 **
0.1414 ± 0.066
1.4790 ± 0.172
Data were analyzed using one-way ANOVAs and t-tests with Bonferroni
corrections; for comparisons between TMX2-28 cells and MCF-7 cells
§
p<0.005; for comparisons between TMX2-28 cells and MDA-MB-231 cells
*p<0.05, **p<0.01, ***p<0.001
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Figure 3.1 TMX2-28 cells do not secrete active MMP-1, -2, and -9. Total RNA was
isolated from TMX2-28, MCF-7, and MDA-MB-231 cells at 80% confluence. Relative
mRNA expression of MMP-1 (A), MMP-2 (B), and MMP-9 (C) were determined by
qRT-PCR and normalized to the housekeeping gene HPRT. Differences among cell lines
were analyzed with one-way ANOVA and post hoc t-tests with a Bonferroni correction;
*p<0.05. (D) Conditioned media was collected from confluent cell cultures grown in
serum-free medium for 48 hours and used for MMP-2 and -9 activity assessment.
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Figure 3.2 Expression of RhoA, ROCK 1, and ROCK 2 are upregulated in TMX2-28
cells. Relative mRNA expression of (A) RhoA, (B) ROCK 1, and (C) ROCK 2 were
determined by qRT-PCR and normalized to the housekeeping gene HPRT. Differences
among cell lines were analyzed with one-way ANOVA and post hoc t-tests with a
Bonferroni correction; **p<0.01. Protein lysates (~20 µg) were probed for RhoA
expression by Western immunoblotting (GAPDH used as loading control).
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Figure 3.3 Blocking RhoA kinase pathway activity with the ROCK inhibitor H-1152
reduces migratory and invasive behavior. TMX2-28, HeLa (positive control) and MCF-7
(negative control) were treated with H-1152 at 0, 20, and 100 µM concentrations for 24
hours. Cells were then seeded into invasion chambers with basal media containing the
respective concentration of inhibitor and incubated for 22-24 hours. Cells were then
fixed, stained and counted. Differences among cell lines were analyzed with one-way
ANOVA and post hoc t-tests with a Bonferroni correction; *p<0.05, **p<0.01,
***p<0.001.
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Figure 3.4 RhoA knockdown in TMX2-28
cells results in inhibition of migration and
invasion. TMX2-28 and HeLa cells were transiently transfected with either a negative
control siRNA (NC-siRNA) or a RhoA specific siRNA (RhoA-siRNA; MCF-7 cells were
not transfected). Forty-eight hours post transfection cells were collected for either
RNA/protein isolation or invasion assay. (A) Relative mRNA expression of RhoA was
determined by qRT-PCR and normalized to HPRT. Protein lysates (~20 µg) were probed
for RhoA expression by Western blotting (GAPDH as loading control). (B) Cells were
seeded into invasion chambers, incubated for 22-24 hours, fixed, stained and counted.
Differences among cell lines were analyzed with one-way ANOVA and post hoc t-tests
with a Bonferroni correction; *p<0.05, **p<0.01, ***p<0.001.
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CHAPTER 4

FURTHER CHARACTERIZATION OF THE TMX2-28 BREAST CANCER
CELL LINE

Introduction
Human breast tumor cell lines are needed for multidisciplinary research in breast
cancer. Cell lines that have been thoroughly characterized are the most useful for
research. The TMX2-28 cell line has been used as a model for breast cancer in a number
of studies including the research in this dissertation. As mentioned in prior chapters,
Fasco and colleagues first characterized these cells following selection of 28 clones
resulting from prolonged exposure of MCF-7 cells to the anti-estrogen Tamoxifen (69).
While the majority of the clones expressed varying ratios of wildtype ERα and its splice
variant ER∆3, one clone, later termed TMX2-28, had completely lost expression of ERα
mRNA and protein. It was noted that these cells grew faster than MCF-7 under standard
culture conditions, had the ability to form foci independently of estradiol or Tamoxifen,
and thus must rely on ER-independent genes and signaling pathways for cell growth (69).
Studies in the Arcaro laboratory continued characterizing these cells by studying
differentially expressed genes resulting from a cDNA microarray comparing TMX2-28
with their parent cell line MCF-7 (68). One thousand four hundred and two transcripts
were found to be differentially expressed greater than two fold in TMX2-28 cells (200
upregulated, 1202 downregulated). Results from this array not only confirmed ERα
down regulation, but also determined that TMX2-28 cells retained expression of luminal

94

cytokeratins 8, 18, 19, and 20, and gained expression of basal cytokeratins 5, 14, and 17
(68), giving them a mixed basal/luminal cytokeratin profile.
Studies for this dissertation research further revealed that TMX2-28 cells fall into
the triple-negative designation (Chapter 2) in that they not only lack ERα expression, but
also lack expression of PR and HER2. Continued investigation revealed that TMX2-28
cells display an altered cell cycle with nearly twice the percentage of cells in the S and
G2/M phases of the cell cycle than the G0/G1 phase, as compared to MCF-7 (68).
Additionally, TMX2-28 cells were found to be highly invasive, as compared to MCF-7,
demonstrated by their ability to invade through Matrigel similar to the highly invasive
MDA-MB-231(67).
An in depth study of specific proteins upregulated in TMX2-28 cells have
identified a number of potential biomarkers (PLD1, PALM) and therapeutic targets
(MIG2, SKP2, RhoA) for ERα-negative and triple-negative breast cancers (Chapter 2 &
3; Ref (67, 68, 101). Alongside the main research described in this dissertation, a number
of genes involved in cell cycle, cell proliferation, anti-hormone resistance, cell migration
and invasion, or are tumor subtype markers were also assessed in TMX2-28 cells.
Expression of cytokeratins (CK) reflects the epithelial cell type, state of tissue
growth, differentiation, and functional status of tissue (149). In normal breast epithelium,
the luminal and myoepithelial (basal) cells express different cytokeratin profiles. Luminal
cells express CKs 7, 8, 18, and 19, while basal cells express CKs 5, 14, and 17 (150-152).
Thus CK 5, 14, and 17 are used to define breast cancer with basal cell origins and tumors
with acquired basal cell characteristics.
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Epidermal growth factor receptor (EGFR) is a member of the epidermal growth
factor receptor superfamily, which promotes tumor cell proliferation and survival in a
variety of cancer types including lung, prostate, head and neck, stomach, kidney, brain,
pancreatic, and breast (153-160). Recent studies have brought EGFR into the forefront of
cancer research due to its high association with poor patient prognosis and its
overexpression in triple-negative, basal-like tumors, making it a standard marker for
basal cell origin (161-166).
C-myc is a proto-oncogene with the ability to transform cells (167). C-myc
encodes a transcription factor that regulates cell proliferation through targeting cyclin/
cyclin dependent kinase (CDK) complexes (168-171) and can drive cells through G1/S
transition in the absence of growth factors (172). Studies have also shown that C-myc
activation can induce apoptosis (167, 173).
The insulin-like growth factor 1 receptor (IGF1R) is a member of the tyrosine
kinase receptor superfamily (174). IGF1R is known to control cell proliferation, ERα
expression, and it is suggested to be involved with cell motility/adhesion and antihormone resistance in breast cancer (175-180). Interference with activation, expression,
or signaling of IGF1R results in inhibition of growth and induction of apoptosis in breast
cancer cells (181).
The cell cycle is based on two key families of proteins, CDKs and cyclins. CDKs
activate downstream signaling through phosphorylation of their target genes; cyclins bind
to CDKs and control their ability to phosphorylate target proteins (182-185). CDK4 is
expressed and has actions in the G1 of the cell cycle. Progression though G1 depends
upon the ability of CDK4 to bind and be activated by Cyclin D (186).

96

FoxM1 is a member of the forkhead box family of transcription factors and
promotes cell cycle progression into the M phase of the cell cycle (187, 188). FoxM1
controls transcription of a number of cell cycle, mitosis and genes responsible for
chromosome segregation including Cyclin B1, Cyclin D1, NEK2, CDC25B, Aurora B
Kinase, and Surviven (187-190). In breast cancer, FoxM1 is known to be elevated and
also to both regulate ERα expression, and to be regulated by ERα (191, 192).
Rac1 and CDC42 are members of the Rho GTPase family. Rac1 induces actin
rich surface protrusions (lamellipodia) and cell ruffling, while CDC42 promotes the
formation of actin-rich membrane extensions (filopodia) (193-196). CDC42 also controls
cell directionality during mesenchymal cell movement through polarizing microtubules
(49). p21 activated kinase (PAK) is a downstream target of both Rac1 and CDC42 (197199). PAK then targets substrates involved in a number of cellular processes including
cell proliferation, survival, motility, angiogenesis, EMT, anchorage independent growth,
and metabolism (199-205).
E-cadherin is a calcium regulated cell-cell adhesion molecule expressed primarily
in epithelial cells (206, 207). Studies have shown that expression of E-cadherin in breast
cancer rescues progression and invasiveness of tumors, and formation of metastases
(208). Inactivation of E-cadherin is characteristic of invasive breast cancer and has been
suggested as a useful prognostic factor for classifying subgroups of triple-negative and
basal-like breast cancers (209-214).
The importance of estrogen signaling in breast cancer progression is well
described (215-218). Estrogens are steroid hormones that regulate growth, differentiation
and function in various tissues throughout the body. Until the discovery of ERβ in 1996,
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it was thought that all biological effects of estrogen were mediated through one receptor,
ERα (215, 216, 219). Human mammary tissue expresses both ER subtypes (219-221).
ERβ is highly homologus to ERα, having 96% amino acid homology at the N-terminus,
and 58% amino acid homology at the C-terminus (219). ERβ can bind estradiol with an
affinity similar to that of ERα and can stimulate transcriptional activation through
estrogen response elements (222). A number of studies have found that ERα-negative
breast cancers with ERβ immunoreactivity respond favorably to adjuvant Tamoxifen
treatment (223-227). Conversely, a number of studies have shown that ERβ can mediate
opposite effects than those of ERα and suppress proliferation (228-230).
The forkhead transcription factor, FoxP3 regulates the development and function
of T regulatory cells (231, 232). Until recently, FoxP3 expression was thought to be
confined to the T cell lineage (231, 233), however studies have since shown that FoxP3 is
expressed in cancer, including breast cancer, melanoma, and cell lines derived from solid
tumors (234-237). Studies from Zuo et. al. have demonstrated that FoxP3 may also act as
a master regulator controlling the expression of the breast cancer oncogenes, SKP2 and
HER2 through transcriptional repression (237, 238). Zuo also noted that FoxP3
heterozygous mice show an increase rate of spontaneous mammary cancer (238). Lastly,
expression of FoxP3 in breast cancer has also been associated with poor patient survival
(239).

Materials and Methods
Cell Culture: TMX2-28 and MCF-7 cells were maintained in T-75 culture flasks
at 37°C and 5% CO2, in Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with calf serum (5%), insulin (10 µg/ml), non-essential amino acids (100X), penicillin-
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streptomycin (10,000 µg/ml), and L-glutamine (200 mM). MDA-MB-231 cells were
maintained in Leibovitz-15 (L-15) medium supplemented with 10% FBS at 37°C and 0%
CO2. Jurkat cells were maintained in RPMI medium supplemented with 10% FBS at
37°C and 5% CO2. All cells were passaged when near 80% confluence.

RNA Isolation: Total RNA (n=3 biological samples) was isolated with TriReagent (Molecular Research Center, Cincinnati, OH) according to manufacturer’s
suggestions and protocols as previously described (67, 68, 101). RNA was then treated
with Turbo DNA-Free (Ambion, Austin, TX) to remove any DNA contamination. The
quality of the RNA was assessed by 260/280 nm spectrophotometer readings (Nanodrop
8000; Thermo Scientific, Wilmington, DE).

Quantitative Real Time Reverse Transcriptase PCR (qRT-PCR): RNA samples
(n=3 biological samples) were reverse transcribed and amplified using the One Step RTPCR kit (Qiagen, Valencia, CA) in the Roche LightCycler (Roche, Indianapolis, IN) as
previously described. Gene specific primers, designed using Primer3 software
(http://frodo.wi.mit.edu/), and purchased from Integrated DNA Technologies, Inc.
(Coralville, IA), were used for CK 5, CK 14, CK17, EGFR, C-myc, IGF1R, CDK4,
FoxM1, CDC42, Rac1, PAK, E-Cadherin, ERβ; primers for FoxP3 were purchased from
SABiosciences (Valencia, CA; Table 4.1).
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Results
Gene expression of markers of basal cells, proliferation, migration/invasion and
hormone signaling in TMX2-28

Using qRT-PCR to determine the gene expression of basal markers, it was
revealed that TMX2-28 cells have significantly higher relative expression of CKs 5, 14,
and 17 than luminal MCF-7 cells and similar levels as basal MDA-MB-231 cells (Table
4.2). Contrary to our prediction, TMX2-28 cells had significantly lower expression of
EGFR than MDA-MB-231 cells. The proliferation markers C-myc, IGF1R, CDK4, and
FoxM1 were also examined for mRNA expression in TMX2-28 cells. No significant
difference in expression of C-myc or FoxM1 was found, however there was a significant
decrease in IGF1R expression compared to MCF-7 and a significant increase in
expression of CDK4 compared to MDA-MB-231 cells (Table 4.2).
I also examined the expression of four genes involved in cell migration, adhesion
and invasion (Rac1, CDC42, PAK, and E-Cadherin). It was determined that TMX2-28
cells express significantly higher levels of Rac1 mRNA than do MCF-7, and similar
levels as those of MDA-MB-231 cells. TMX2-28 also had significantly less PAK
expression than MCF-7 cells, and although not significant, they have higher expression of
PAK than MDA-MB-231 cells. These cells were also found to have significantly less
expression of CDC42 than MDA-MB-231 cells (Table 4.2). Lastly, TMX2-28 cells were
found to express significantly less E-cadherin mRNA than MCF-7 cells, not significantly
different from MDA-MB-231 (Table 4.2; Figure 4.1).
Further gene expression studies revealed that TMX2-28 cells have little to no
expression of ERβ, similar to MCF-7, and significantly less than MDA-MB-231 cells,
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which are considered ERβ-positive (Table 4.2). Figure 4.2 shows that compared to
expression of ERβ in human tissues (prostate and testis), TMX2-28 cells lack ERβ
expression. Lastly, relative FoxP3 expression was also determined. FoxP3 was found to
be significantly less expressed in TMX2-28 cells when compared to MCF-7 and Jurkat T
lymphocyte cells, both of which are known to be FoxP3 expressing cells (Table 4.2;
Figure 4.3).

Discussion
A great advantage to cancer research has been the development of the ability to
culture tumor cell lines in an in vitro setting. With this technology, researchers have been
able to examine the effects of manipulating the levels of oncogenes, proto-oncogenes,
and suppressor genes on behavioral properties. They can then compare in vitro properties
with those in human cancer tissue, and investigate the mechanisms that differ between
them to determine which cell line best mimics the cancer of interest. In this chapter, gene
expression of basal cell markers, genes associated with cell proliferation, hormone
signaling, migration, adhesion, and invasion were examined in TMX2-28 cells in order to
further characterize this cell line as a model for triple-negative and basal-like breast
cancers.
It was discovered that TMX2-28 cells express a number of basal cell markers, CK
5, 14, and 17, and the proliferation marker CDK4. Expression of one gene associated
with invasion, CDC42, was found to have low expression in TMX2-8 cells. This was not
surprising as CDC42 is known to play an important role in protease-dependent,
mesenchymal invasion and as I have shown in Chapter 3, TMX2-28 utilizes a proteaseindependent, amoeboid invasion mechanism. The mRNA expression of the adhesion
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protein E-Cadherin was also determined to be at low expression levels in TMX2-28 cells.
Gene expression assays also revealed that TMX2-28 cells do not express ERβ, suggesting
that they truly rely on ER independent growth mechanisms. Lastly, TMX2-28 cells do
not express the transcription factor FoxP3, suggesting that FoxP3 regulates neither SKP2
nor HER2 expression in TMX2-28 cells. The gene expression profiling in this chapter
has revealed a number of unique expression patterns in the TMX2-28 breast cancer cells
line. These patterns help explain the hormone-independent and Tamoxifen insensitive,
uncontrolled aggressive growth phenotype associated with ERα-negative, triple-negative,
and basal-like breast cancers.
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Table 4.1
Primers used to detect relative mRNA expression of genes
Gene
RefSeq
Forward
Reverse Sequence
Number
Sequence (5'-3')
(5'-3')
CK 5
NM_000424.3
CAACCCACTAG ATAGCCACCCA
TGCCTGGTT
CTCCACAAG
CK 14

NM_000526.4

CK 17

NM_000422.2

EGFR

NM_005228.3

C-myc

NM_002467.4

IGF1R

NM_000875.3

CDK4

NM_000075.3

FoxM1

NM_202002.2

CDC42

NM_00103980
2.1

Rac1

NM_018890.3

PAK2

NM_002577.4

ECadherin

NM_004360.3

ERβ

NM_001437

FoxP3

NM_014009.3

TTCTGAACGAG GCAGCTCAATC
ATGCGTGAC
TCCAGGTTC
GCTGCTACAGC TCACCTCCAGC
TTTGGGCTCT
TCAGTGTTG
TTCCCGTAATTA ACCCCTAAATG
TGTGGTGACAG
CCACCGGC
ATC
TTCGGGTAGTG CAGCAGCTCGA
GAAAACCAG
ATTTCTTCC
TCATCCGCAAC TGGCGCCCTTT
GGCAGCCAG
AGTCCCCGT
TTTCCGCGCGCC GACGTCCATCA
TCTTTGGC
GCCGGACAACA
GGAGGAAATGC TAGGACTTCTT
CACACTTAGCG GGGTCTTGGGG
TG
CCAACGCCCCG TCAGGCACCCA
GTGGAGAAG
CTTTTCTTTCAC
G
GTGGTGGGAGA TGAGTGCGAAG
CGGAGCTGTA
GCTCCACCG
TGCACTGGGAC
AGGAGGTTGCT
CGCCCCATCAG
GCCTCCGTT

GCGTTTGCTCT
GCTCAGGGGT
CAGCCTCCCAC
GCTGGGGTA

ACCTTCCTTTTC
AGTGTCTCTC

CCATCGCCAGT
TATCACATCT

SABiosciences Cat# PPH00029B
(Start position lies in exon 12)
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Table 4.2
Relative mRNA expression of epithelial to mesenchymal genes in cell lines
MDA-MBTarget
Function
TMX2-28
MCF-7
231
1.259 ± 0.438†

0.002 ± 0.001

0.142 ± 0.047

5.431 ± 0.982a

0.045 ± 0.033

6.906 ± 2.456

2.262 ± 0.527

0.007 ± 0.004

0.581 ± 0.157

EGFR

0.017 ± 0.008***

0.007 ± 0.001

0.101 ± 0.011

C-myc

0.523 ± 0.226

0.056 ± 0.013

0.189 ± 0.058

IGF1R

0.024 ± 0.013†††

0.256 ± 0.026

0.014 ± 0.003

CDK4

0.175 ± 0.011*

0.171 ± 0.002

0.078 ± 0.027

FoxM1

4.871 ± 1.600

1.736 ± 0.831

2.373 ± 1.054

CDC42

0.217 ± 0.010***

0.228 ± 0.019

0.708 ± 0.066

0.968 ± 0.251†

0.105 ± 0.029

0.953 ± 0.188

0.002 ± 4.607 x
10-4 †

0.004 ± 4.01 x 8.89 x 10-6 ±
10-4
2.759 x 10-6
7.68 x 10-6 ±
0.098 ± 0.019
3.045 x 10-6
1.989 x 10-5 ± 5.096 x 10-5 ±
1.596 x 10-6
4.877 x 10-6

CK 5
CK 14
CK 17

Basal Cell
Markers

Proliferation

Rac1
PAK2
ECadherin

Migration,
Adhesion,
Invasion

††, *

Jurkat

N/A

N/A

0.006 ± 0.003††

N/A

Estrogen
1.051 x 10-5 ±
N/A
Signaling
1.871 x 10-6 ***
Regulation
0.009 ± 0.006†††,
0.238 ±
FoxP3
0.604 ± 0.030
N/A
of SKP2
¶
0.029
and HER2
Data were analyzed using one-way ANOVAs and t-tests with Bonferroni corrections; for
comparisons between TMX2-28 cells and MDA-MB-231 cells *p<0.05, **p<0.01,
***p<0.001; for comparisons between TMX2-28 and MCF-7 cells †p<0.05, ††p<0.01,
†††p<0.001; for comparisons between TMX2-28 and Jurkat cells ¶p<0.001; §only one
biological sample was available for assaying; a Significant ANOVA (p<0.05) but not
significant with post hoc t-tests. .
ERβ
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Figure 4.1 E-Cadherin is downregulated in TMX2-28 cells. Relative mRNA expression
of E-Cadherin was determined by qRT-PCR and normalized to the housekeeping gene
HPRT. Differences among cell lines were analyzed with one-way ANOVA and post hoc
t-tests with a Bonferroni correction; **p<0.01.
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Figure 4.2 ERβ is downregulated in TMX2-28 cells. Relative mRNA expression of ERβ
was determined by qRT-PCR and normalized to the housekeeping gene HPRT.
Differences among cell lines were analyzed with one-way ANOVA and post hoc t-tests
with a Bonferroni correction; NS= not significant. ***p<0.001.
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Figure 4.3 FoxP3 is downregulated in TMX2-28 cells. Relative mRNA expression of
FoxP3 was determined by qRT-PCR and normalized to the housekeeping gene HPRT.
Differences among cell lines were analyzed with one-way ANOVA and post hoc t-tests
with a Bonferroni correction; ***p<0.001.
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CHAPTER 5

TUMORIGENICITY AND METASTATIC POTENTIAL OF TMX2-28 CELLS

Introduction

Previous studies have validated that MCF-7 cells respond to estrogen (17β
estradiol; E2) in vivo in xenograft model systems in mice by inducing tumor growth (240,
241). Thus, I established a collaboration with the laboratory of Dr. Sallie SmithSchneider to test TMX2-28 and SKP2 knockdown TMX2-28 cells for their in vivo
tumorigenicity and metastasis potential in mouse xenograft models. Based on the highly
proliferative and invasive nature of TMX2-28 cells, and the data we have showing that
suppressing SKP2 alters their cell cycle and thus decreases proliferative potential, it is
predicted that TMX2-28 and TMX2-28-NC (negative control) cells will establish tumors
of larger size and volume than MCF-7 and TMX2-28-S2 (SKP2 knockout cells).

Materials and Methods

Xenograft assays for tumorigenicity: For the first set of xenograft studies, two
groups of 10, 5-week-old) athymic nude mice (Jackson Laboratories, Bar Harbor, ME)
received subcutaneous inoculations of cells without E2 supplementation. For group 1,
inoculations consisted of 2 x 106 TMX2-28 or MCF-7 cells in 100 µL of Hank’s balanced
salt solution, injected into the right and left flank, respectively. For group 2, each
inoculation consisted of 2 x 106 TMX2-28-NC or TMX2-28-S2 cells in 100 µL of Hank’s
balanced salt solution, injected into the right and left flank, respectively. During this
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twenty-four day assay, mice were manually palpated beginning at day 3 post injection
and every 3-4 days after.
For the second set of xenograft studies, a group of 10, 6-week-old non-obese
diabetic background severe combined immune deficient (NOD-SCID) mice (Jackson
Laboratories, Bar Harbor, ME) received subcutaneous inoculations of cells without
estrogen supplementation. Each inoculation consisted of 2 x 106 TMX2-28-NC or
TMX2-28-S2 cells in 100 µL of Hank’s balanced salt solution, injected into the right and
left flank, respectively. During this sixty-two day assay, mice were manually palpated
beginning at day 3 post injection and every 3-4 days after. IACUC approval was
obtained for all work with animals.

Results
TMX2-28 cells were unable to sustain palpable tumors in xenograft models

Xenograft studies for tumorigenicity revealed that TMX2-28 cells, regardless of
SKP2 expression levels, were unable to sustain appreciable tumor growth. The first set
of xenograft studies involved evaluation of tumorigenesis potential of TMX2-28 versus
MCF-7 cells (Group 1) and the potential of TMX2-28-NC versus TMX2-28-S2 cells
(Group 2) in the absence of E2 in athymic nude mice. Following the twenty-four day
study, growth size at the sight of injection steadily decreased from all 20 mice with
possible tumors 4 days post injection to 10 (day 12), 5 (day 15), 1 (day 18), and finally
zero by day 21. Although none of the mice produced sustainable palpable tumors, upon
surgical evaluation, seven mice had small growths at the site of injection, four of which
were injected with TMX2-28 cells, and the remaining three were injected with TMX2-
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28-S2 cells. These seven growths were collected, fixed and embedded in paraffin along
with the lungs and livers of all twenty mice, and are available for further study.
The second set of xenograft studies only involved evaluation of tumorigenesis
potential of TMX2-28-NC versus TMX2-28-S2 cells in the absence of E2 in NOD-SCID
mice. During this 62-day study, “possible” tumors were manually detected in 8 of the 10
mice by 6 days post injection. This number increased to 9 mice by day 9, however
steadily it decreased to 5 (day 13), 3 (day 16), 1 (day 20), and finally 0 mice by day 24.
The majority of mice began to develop tumors even though they were not sustainable.
Upon surgical evaluation, three mice had small growths at the site of injection, two
injected with TMX2-28-S2 and one injected with TMX2-28-NC cells. One of the mice
with the TMX2-28-S2 injection site growth also had an abdominal growth present. For
this study a number of organs that are frequent sites of breast cancer metastasis (brain,
liver, and lungs) were collected along with the four growths; the tissue at the injection
site, and the surrounding mammary glands (lower glands). These tissues have been fixed,
embedded in paraffin and are available for further study.

Discussion

Xenograft studies for tumorigenicity revealed that TMX2-28 cells, regardless of
SKP2 expression levels, were unable to sustain appreciable tumor growth following
subcutaneous flank injections into xenograft mouse models. During both studies,
possible tumors were manually detected in mice by 6 days post injection, but ultimately
all mice lost them by day 24.
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Knowing that TMX2-28 cells are triple-negative, have a mixed basal/luminal CK
expression profile, and are highly proliferative and invasive when cultured in vitro, we
would expect this cell line to establish sustainable tumors in a xenograft mouse model.
Surprisingly, they did not. One other study has also evaluated the in vivo tumorigenicity
of TMX2-28 cells. Spink and colleagues inoculated the mammary glands of 6- and 8week-old SCID mice, with and without E2 supplementation. They too observed that
TMX2-28 cells grew poorly as mammary gland xenografts regardless of E2
supplementation (242).
Given that TMX2-28 cells are highly proliferative and invasive in vitro, that the
majority of mice began to develop tumors even though they were not sustainable, and
that both studies had a few mice with small growths upon surgical evaluation, it is
reasonable to suggest that these cells may not have formed substantial tumors at the
injection site for two reasons: 1. The cells had already left the “primary” tumor site to
establish metastatic niches throughout the body or 2. The cells lack expression of genes
that are critical to the process of growth in the in vivo setting.
To address the first hypothesis, a number of tissues were collected after both
xenograft assays and were fixed in formalin and embedded in paraffin. With these tissues
we can exploit the fact that the shRNA construct used to stably transfect TMX2-28 cells
also contains a GFP gene, which results in GFP expression in the control and SKP2silenced cell lines (TMX2-28-NC andTMX2-28-S2). Anti-GFP antibodies could be used
to evaluate the presence or absence of TMX2-28 cells in the various organs collected.
Observations that these cells were able to establish metastatic growths would fit with the
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aggressive and highly metastatic nature of triple-negative and basal-like tumors seen in
breast cancer patients.
It is equally possible that TMX2-28 cells grew poorly in xenograft models simply
because they were unable to successfully establish in an in vivo setting. If this were the
case then deciphering why they are unable to grow would be instrumental in designing
targetable therapy to combat tumor growth and metastasis. It is known that MCF-7 cells
(TMX2-28’s parent cell line) are typically non-invasive but will form tumors in vivo in
the presence of E2 (242-244), so what is lacking in TMX2-28 cells that made them loose
this ability? To address this hypothesis, further studies comparing MCF-7 and TMX2-28
cells are needed. Our lab has both cDNA and methylation array data that compare the
parent and derivative cell lines. Looking for genes that are related to growth and
metastasis and that are downregulated and/or promoter-methylated in TMX2-28 as
opposed to MCF-7 would be the first place to start.
Additionally, it may be advantageous to compare these cells with another triplenegative cell line that is known to form xenograft (i.e. MDA-MB-231). Another
direction would be to study other Tamoxifen-selected lines such as the TMX2-11 and
TMX2-4 cell lines, which were created alongside TMX2-28, or to look at cells during the
process of Tamoxifen selection. These cells could shed light on the pathway genes that
were altered and are preventing TMX2-28 cells from growing in vivo. If we can
determine why these cells do not form primary tumors in vivo, we will have a greater
understanding of how to target aggressive types of cancers in patients.
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CHAPTER 6
DISCUSSION AND FUTURE DIRECTIONS
Introduction

Breast cancer is a heterogeneous disease that varies in its biology and response to
therapy. Homeostasis of non-cancerous cells requires a delicate balance between
proliferation, cell cycle arrest and apoptosis; this equilibrium is disrupted during cancer
progression. Historically, estrogen receptor (ERα), progesterone receptor (PR), and
human epidermal growth factor receptor 2 (HER2) are the most important prognostic
factors in breast cancer, dictating a patient’s therapeutic options. Currently, breast
tumors are further classified into subtypes based on their gene expression patterns (7, 11).
One tumor subtype lacks expression of ERα, PR, and HER2 and is referred to as triplenegative. The basal-like tumor subtype is associated with positive basal cytokeratin (CK)
expression and is often triple-negative (7, 16, 78-80). Patients with these subtypes face
poor prognosis, as these cancers are typically aggressive in their growth, highly
metastatic and often unresponsive to anti-estrogen and anti-HER2 therapies (17, 18). The
data presented here was designed to answer questions specifically related to growth and
invasion in triple-negative and basal-like breast cancers, with the objective of furthering
our understanding of the molecular mechanisms underlying these processes.
In this study, we use the Tamoxifen-selected, MCF-7 derivative, TMX2-28 breast
cancer cell line. TMX2-28 cells have lost expression of ERα and have acquired a mixed
basal/luminal cytokeratin profile, suggestive of a more basal-like phenotype (32-34).
Morphologically, TMX2-28 cells retained an epithelial cell shape similar to MCF-7.
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Behaviorally, TMX2-28 cells are highly proliferative and invasive (32, 33). It is these
characteristics that make TMX2-28 cells an interesting and relevant model for studying
increased growth and invasive behavior in triple-negative and basal-like breast cancers.
It was also discovered that TMX2-28 cells express a number of basal cell
markers, CK 5, 14, and 17, and the proliferation marker CDK4. Additionally, low
expression (mRNA) of one gene associated with invasion, CDC42, and the adhesion
protein E-Cadherin also was found in TMX2-28 cells. Gene expression assays also
revealed that TMX2-28 cells do not express ERβ, suggesting that they truly rely on ERindependent growth mechanisms. Lastly, TMX2-28 cells do not express the transcription
factor FoxP3, suggesting that SKP2 and HER2 expression is not regulated by FoxP3 in
TMX2-28 cells.

SKP2 Mediates Proliferation In Vitro and is Associated With Aggressive Breast
Cancer Subtypes

S-phase kinase-associated protein 2 (SKP2) plays an important role in cell cycle
regulation by targeting p27 for degradation (21, 28, 35, 36). During the transition from
G1 to S phase, p27 undergoes phosphorylation modifications at three major sites, Serine
10 (Ser10), Threonine 187 (Thr187) and Threonine 198 (Thr198) (29). Phosphorylation
at Ser10 stabilized p27 in quiescent cells, however, this phosphorylation event has been
shown to promote cell proliferation (29-32). Thr198 phosphorylation is catalyzed by
ROCK 1 kinase, only when Ser10 is already phosphorylated, and results in the
inactivation of both free and CDK bound p27 (33, 34). Lastly, phosphorylation of
Thr187 is catalyzed by SKP2 and promotes the ubiquitin ligase-mediated degradation of

114

p27 (21, 28, 35-39). The cyclin-dependent kinase (CDK) inhibitor p27 regulates G1/S
transition by binding cyclin/CDK complexes and abrogating its activity (21, 35, 36).
Overexpression of SKP2 has been associated with poor prognosis on its own (94) and in
combination with high Cyclin E expression (92) as well as other unfavorable prognostic
factors including increased tumor grade, lack of expression of ERα and PR, and HER2
overexpression (95, 96).
The primary objective of the present study was to provide insight into the
oncogenic role of SKP2 in triple-negative and basal-like breast cancers. To accomplish
this, we first evaluated SKP2 expression in a triple-negative, basal-like breast cancer cell
line TMX2-28 (Chapter 2). We found significantly higher SKP2 levels in TMX2-28
cells, and that these cells overexpress a number of SKP2 pathway proteins including p27,
CDK2, and Cyclin E, but did not overexpress an alternative cell cycle pathway protein
Cyclin D1. We also discovered that partially blocking SKP2 expression in TMX2-28
cells using RNAi results in altering their cell cycle pattern by decreasing the percentage
of cells in the S phase and increasing the percentage of cells in the G1/G0 phase of the cell
cycle.
Another way we could establish that SKP2 overexpression is resulting in the
increase of G1/S transition in TMX2-28 cells is to examine the activity of CDK2. CDK2,
in complex with Cyclin E is responsible for G1/S transition through the phosphorylation
of a number of proteins including the retinoblastoma (Rb) (245). In order for
CDK2/Cyclin E to have its kinase actions on Rb, CDK2 must first be activated though
phosphorylation of Thr160. Cyclin E binding to CDK2 results in conformational changes
that reduced steric hindrance around Thr160 allowing the residue to be available for
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phosphorylation by Cyclin Activating Kinase (246-250) Thus to show activation of
CDK2, protein expressions of activated CDK2 (Thr160 phosphorylated CDK2) and
phosphorylated Rb could be examined.
Additionally, we assessed mRNA and protein expression of SKP2, and its
associated proteins, in human breast and breast cancer tissues. SKP2 mRNA was found
to be more frequently expressed in ERα-negative, basal cytokeratin expressing, and
basal-like breast cancers. Using IHC and TMA methods, we also evaluated the
relationships between SKP2 and its pathway genes as well as the relationship between
SKP2 and several clinicopathological features. High levels of SKP2 did not always result
in low levels of p27. In our study 11% of tumors expressed high SKP2/low p27,
however, 32% of tumors with high SKP2 also had high p27. Furthermore, low levels of
SKP2 were associated with low p27 in 20% of the tumors. While we found no
significant relationship (neither positive nor inverse) between SKP2 and p27 expression,
a significant positive relationship was discovered between SKP2 and the phosphorylated
form of p27 (pSer10p27), a form of p27 associated with increased proliferation rates (30,
38).
Taken together with the work from other groups, these findings strongly suggest
that SKP2 could play a vital role in the progression of triple-negative and basal-like
breast cancers. The next step in this study would be the evaluation of p27
phosphorylation in TMX2-28 cells and human breast tissues. The relationships between
SKP2 overexpression and pThr187p27, pSer10p27/pThr187p27 double phosphorylation,
and pSer10p27/pThr198p27 double phosphorylation needs to be determined.
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In vitro studies would involve immunoprecipitation of pSer10p27 using the same
anti-pSer10p27 monoclonal antibody used for IHC studies in Chapter 2 (ab62364;
Abcam, Cambridge, MA). The resulting protein can then be run out on a Western
immunoblotting gel and probed for either pThr187p27 or pThr198p27. For this assay I
would suggest using Abcam’s anti-pThr187p27 (ab118644) and anti-pThr198p27
antibodies (ab64949; Abcam, Cambridge, MA). Although Abcam’s antibody is not
backed by literature yet, I was unable to optimize the antibody for pThr187p27 that is
seen in literature (sc-16324, Santa Cruz Biotechnology, Inc., Santa Cruz, CA) for either
Western blotting or IHC (251-253).
It would also be advantageous to evaluate the expression of these pThr187p27 and
pThr198p27 in breast and breast cancer tissues (as performed in Chapter 2) and see if its
expression correlates with age, tumor type, tumor grade, ERα and triple-negative status,
and SKP2 expression using the same antibodies as above and consecutive slices of tissue
samples. Alternatively, sequential antibody staining of tissue could be performed in
order to visualize multiple proteins (Ser10, Thr187, Thr198, and SKP2) within the same
tissue slide. This could be done using secondary antibodies with different fluorophores
attached to them. Potential problems with this approach include cross contamination, and
limitations on the antibodies that are available for the phosphorylated forms of p27.
SKP2 overexpression could modulate the malignant phenotype of triple-negative
and basal-like breast cancers through direct and indirect regulation of p27
phosphorylation. SKP2 is known to directly regulated p27 through SCF/E3 ligase
activity (resulting in pThr187p27), however SKP2 may be indirectly regulating the p27
inactivation thorough its ability to stimulate RhoA transcription. Increased RhoA leads
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to increased activation of its downstream effectors ROCK 1/2 and mDia, which in turn,
not only activates SKP2 transcription but ROCK 1 also catalyzes the phosphorylation of
pSer10p27 at Thr198 resulting in the inactivation of p27.
The results from these additional studies would help elucidate the extent to which
combined high levels of SKP2 and pSer10p27 alone, in combination with pThr187p27
and/or pThr198p27 may be a good indicator of whether inhibiting SKP2 will result in
slowing cell cycle and proliferation. Knowledge of these relationships may further
delineate SKP2 as a suitable and favorable target for the development of specific
therapeutic intervention; providing a molecular signature that would predict which
patients will benefit from SKP2-targeted therapy.

RhoA is Vital to the Invasion Mechanism of TMX2-28 Cells

A foremost threat to patients is tumor invasion and metastasis, with the greatest
risk to patients diagnosed with triple-negative and basal-like breast cancers. To manifest
their malignant potential, tumor cells must have the ability to invade the extracellular
matrix (ECM), enter the blood or lymphatic system, travel to and invade distant tissues,
and establish new tumor sites (41-43). Two distinct morphological/functional
mechanisms are known for single cell migration in tissues: fibroblast-type mesenchymal
invasion, and leucocyte-type amoeboid invasion. Mesenchymal movement is
characterized by an elongated cellular shape, and involves the use of proteases that cause
cellular lysis in tissues, thereby creating a path through which cells can invade (44-47).
Amoeboid migrating cells have a rounded morphology and their movement is protease–
independent; instead, cells find paths through the ECM by pushing and squeezing
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through regions of adequate size (43, 44, 47, 51, 52). Proteins that control cell-cell and
ECM interactions also are thought to play a role in invasion and metastasis in a
proteolytic-independent way, by controlling cell morphology, motility, and interactions
with the tumor microenvironment (41, 44).
The primary objective of the present study was to better define the molecular
aspects underlying invasion, in TMX2-28 cells as a model of triple-negative, basal-like
breast cancer. Despite their aggressive phenotype, TMX2-28 retains morphology similar
to non-aggressive MCF-7 cells, suggesting that their invasion may be proteolyticindependent. We determined that TMX2-28 lack MMP-1 mRNA, and MMP-2/MMP-9
protein expression; each of which are important in protease-dependent invasion. It is
important to note, however, that the activity of other MMPs (i.e. collagenases,
stromelysins, membrane type, and others), as well as other proteases (i.e. serine/threonine
proteases), have not yet been examined in TMX2-28.
TMX2-28 cells have low expression of other genes key to protease-dependent
invasion such as Slug, Zeb 1, Zeb 2, Vimentin, Fibronectin and N-cadherin. Conversely,
these cells have high expression of protease-independent invasion genes such as Rho,
ROCK 1, ROCK 2, and E-cadherin. Finally, treating TMX2-28 cells with a RhoA
pathway inhibitor or shRNA targeting RhoA, significantly reduces their invasiveness.
These data suggest that TMX2-28 cells use a RhoA dependent, proteolyticindependent invasion mechanism. However, additional studies are still needed to
definitively state that TMX2-28 cells move in an amoeboid fashion. One such study
would involve live cell microscopy. Live cell microscopy would allow us to observe
TMX2-28 cell movement in a 3D matrix and thus determine if movement is characteristic
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of amoeboid or mesenchymal invasion mechanisms. For these studies, collaborations
were established first with Dr. Dominique Alfandari. However, we were unable to
complete these studies because we were unable to replicate optimal culture conditions
while cells were at the microscope thus we were unable to keep the cells alive long
enough to observe movement.
A new collaboration was established with Dr. Sallie Smith Schneider at the
Pioneer Valley Life Sciences Institute to use their microscope that included a heated
microscope stage and the ability to regulate CO2 levels. Working with Nicholas
Panzarino, we have begun the process of optimizing the conditions for live microscopy
(Matrigel thickness, concentration of cells, length of recording time, etc.).
Following microscopy studies, there are a number of directions in which this
research can go. If microscopy does not confirm amoeboid movement, then the next step
would be to determine whether these cells undergo epithelial-to-mesenchymal transition
(EMT) when in a 3D environment. This could be done by examining MMP and protease
expression and activation, as well as expression of genes known to change during EMT
in TMX2-28 cells cultured in a 3D matrix. However, this would still leave us with the
initial problem that targeting mesenchymal movement is insufficient because cells can
switch to amoeboid movement when challenged with protease inhibitors (47).
If microscopy confirms amoeboid movement then we would need to further
define the possible interacting proteins involved in this invasion mechanism in order to
design effective targets. For example, RhoC is another member of the Rho superfamily
that has 95% homology to RhoA and a higher affinity and specificity to RhoA’s main
target genes, ROCK 1 and ROCK 2 (254-256). The activation of the ROCKs by RhoC
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has been shown to lead to the disruption of adherens junctions and increased cell motility
and enhanced F-actin assembly (255). Overexpression of RhoC has been observed in
bladder, ovarian, head and neck, pancreatic, hepatocellular, esophageal, and breast cancer
(257-262). Given that RhoC plays a role in cell motility, at least partially through the
same downstream effectors (ROCK 1 & 2) as RhoA, it is possible that RhoC may also be
involved in the amoeboid invasion mechanism.
Another example is RhoE. RhoE was the first member of the Rho kinase family
to be identified (129). Unlike the other family members, RhoE does not act as a classic
GTPase switch, as it does not hydrolyze GTP (129-131). RhoE functions by binding to
and inhibiting the RhoA effector ROCK 1 (but not ROCK 2). This interaction also
results in the phosphorylation of RhoE by ROCK 1, which increases RhoE’s stability and
activity (73, 132). In addition, RhoE binds to p190RhoGAP and increases its activity
toward RhoA, thus promoting the formation of inactive GDP-bound RhoA (133).
RhoC appears to work in concert with RhoA to promote cell motility, while RhoE
seems to be a negative regulator of motility via inhibition of RhoA. With this
knowledge, we can design inhibiting molecules that mimic the actions of RhoE and target
RhoA/C resulting in down regulation and abrogation of invasive behaviors. Then we
could engineer breast cells that have the ability to grow in an in vivo setting, to express
varying levels of the target gene and evaluate the efficacy of the designed inhibitors on
these cells. Targeting the Rho pathway may provide therapeutic strategies that could be
used individually or in combination with protease inhibitors in patients with increased
risk of metastasis.
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SKP2 and RhoA Work Jointly to Produce the Aggressive Phenotype of TripleNegative and Basal-Like Breast Cancers

The research outlined in this dissertation suggests individual and critical roles of
SKP2 and RhoA on proliferation and invasion (respectively) of triple-negative and basallike breast cancers. One point of study that must also be considered and evaluated is that
SKP2 and RhoA have been shown to regulate the transcription of each other (263, 264).
A number of studies between 1993 and 2001 observed that Rho family proteins were vital
for progression through the G1 phase of the cell cycle. RhoA was reported to downregulate both p21 and p27 and stimulate Cyclin D1 accumulation (265-269). The
downstream effectors causing these affects were unknown until studies by Mammato and
colleagues deciphered that RhoA, through its target genes ROCK 1 & 2 and mDia, were
stimulating the transcription of SKP2 in late G1 phase and thus mediating cell growth
(263). Another study by Chan et. al. in 2010 demonstrated that SKP2 cooperated with Cmyc to induce transcription of RhoA independently of the SCFSKP2/E3 ligase activity
(264). SKP2 and C-myc were found to induce transcription of RhoA through recruitment
of the transcriptional co-regulators, Miz1 and p300 to the RhoA promoter (264). Data
from Mammoto and Chan suggest that SKP2 and RhoA work in concert to regulate cell
growth and invasive potential.
In our triple-negative, basal-like breast cancer cell model TMX2-28 both SKP2
and RhoA are overexpressed. Given that SKP2 can induce the transcription of RhoA and
vice versa, it is not unreasonable to suggest that there is a positive feedback loop
occurring that is driving the overexpression of both genes in this cell line (Figure 6.1).
Two questions that need to be evaluated are, when SKP2 is suppressed in TMX2-28 cells,
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what happens to the expression of RhoA, and what is the effect on invasion potential
(using TMX2-28-S2 and TMX2-28-MC cells)? If this positive feedback loop were in
play, than we would expect that knocking down SKP2 would also have resulted in
decreased expression of RhoA and inhibition of invasion. Evaluation of the interactions
of SKP2 with C-myc, p300, Miz1, and/or the RhoA promoter could be performed in the
SKP2 knockdown cells by immunoprecipitation and CHIP analysis. Our studies also
indicate that SKP2 overexpression is correlated with triple-negative breast cancers, thus it
would be advantageous to see if the relationship between SKP2 and RhoA translates to
human samples.
Recently Yamamura et. al. discovered that microRNA-34a could suppress the
assembly and function of SKP2/C-myc/Miz1 complex (270, 271). Likewise, microRNA31 has been shown to suppress breast cancer metastasis partially through down regulation
of RhoA (272). Studies of the expression and activity of these microRNAs would add to
the knowledge of how growth and metastasis is regulated in triple-negative and basal-like
breast cancers.
Lastly, findings by Mohanty and colleagues indicated that the potency at which
p27 inactivates CDK2 is controlled through C-terminal phosphorylation (Thr197/8) by
ROCK but only when p27 was phosphorylated at Ser10 in advance. When p27 was
doubly phosphorylated (Ser10 and Thr197/8) it could no longer inactivate CDK2 and
thus promoted S phase transition of the cell cycle (253). Our studies elucidated that
TMX2-28 cells overexpress ROCK 1 & 2, that suppression of SKP2 in these cells
completely abolished pSer10p27 and that there was a positive correlation between SKP2
and pSer10p27 in human triple-negative tumors. Our data, together with Mohanty’s
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evokes the question of the role of ROCK phosphorylation of p27 in these breast cancer
subsets. ROCK’s involvement in the process of p27 degradation would add to our
finding that regulation of p27 is vital to the proliferative nature of triple-negative and
basal-like breast cancers.
The results of these studies could provide additional important information about
patients with aggressive breast cancer subsets. Collectively, the data presented here
demonstrate the roles of SKP2 and RhoA in triple-negative and basal-like breast cancers
and that both genes make desirable therapeutic targets. However, additional studies are
needed to provide a full understanding of the mechanisms behind cell growth and
metastases, and how the proteins involved in these processes interact and regulate each
other.
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Figure 6.1 Model of how SKP2 and RhoA work in concert to regulate cell growth and
invasive potential. SKP2, independent of its SCF/E3 ligase activity, can complex with Cmyc and Miz1 to activate the transcription of RhoA. RhoA’s downstream effectors,
Rock1/2 and mDia can stimulate the transcription of SKP2. This positive feedback loop
could drive the overexpression of both SKP2 and RhoA and subsequent dysregulation of
proliferation and invasion.
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APPENDIX A

DIFFERENCES IN SCORING IMMUNOREACTIVITY OF SKP2 AND p27 IN
BREAST CANCER
Differences in scoring immunoreactivity of SKP2 and p27 in breast cancer
Scoring for
Scoring for
SKP2 & p27 Relationship
SKP2
p27
Author
Year
N
Significance
(Intensity;
(Intensity;
!!!
!"!
"!!
""!
Distribution) Distribution)
Hi/Lo;
Hi/Lo;
2002
83
1(4%)
21(25%) 30(36%) 32(35%)
Inverse
>/<10%
>/< 50%
Signoretti
High SKP2 in ERα-negative 12/18 (67%), Low in ERα-positive 7/47 (15%)
Hi/Lo;
Hi/Lo;
Zheng
2005
82
8(10%)
45(55%) 23(28%)
6(7%)
Inverse
>/<50%
>/< 50%
Hi/Lo;
Hi/Lo;
Slotky
2005
43
3(7%)
15(35%) 22(51%)
3(7%)
Inverse
>/<10%
>/< 50%
Pos/Neg;
Pos/Neg;
2006
338 63(19%) 116(34%) 45(55%) 114(34%)
None
>/<5%
>/<50%
Traub
No significant association seen with ERα status
Sonoda
2006
Hi/Lo
N/A
137 14(10%) 52(38%) 38(28%) 33(24%)
No stats
Voduc
2008
Hi/Lo
N/A
N/A
N/A
N/A
N/A
N/A
None
Davidovich 2008
Hi/Lo
N/A
40 10(25%) 7(17.5%) 22(55%) 1(2.5%)
Inverse
2008 Hi/normal/low Normal/low 1598
N/A
208(13%)
N/A
N/A
Inverse
Ravaioli
ERα-negative
N/A
N/A
N/A
119(80%)
N/A
N/A
N/A
ERα-Positive
N/A
N/A
N/A
87(54%)
N/A
N/A
N/A
Hi/Lo;
Hi/Lo;
2012
159 51(32%) 18(11%) 58(36%) 32(20%)
None
>/<50%
>/<50%
Fagan-Solis
Pos/Neg;
Pos/Neg;
2012
159 92(58%)
6(4%)
54(34%)
7(4%)
None
>/<50%
>/<50%

126

APPENDIX B

H-1152 INHIBITOR DOSE RESPONSE MIGRATION ASSAYS
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Notes: HeLa and TMX2-28 cells were treated with H-1152 at noted concentrations for
48 hours without media change.
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APPENDIX C

ZYMOGRAPHY PROTOCOL

Precast gelatin gels-BioRad (Cat# 161-1167)
Buffers:
1. Running Buffer (10x Stock)
Tris Base
Glycine
SDS
Ultra Pure H2O

15g
72g
5g
~500ml

(pH should be around 8.3)
2.
3.
4.
6.

Sample Buffer- From BioRad (Cat# 161-0764)
Renaturing Buffer- From BioRad (Cat# 161-0765)
Developing Buffer- From BioRad (Cat# 161-0766)
Staining Buffer- 40% Methanol, 10% Acetic Acid, 0.5% Coomassie Blue, 49.5%
Ultra Pure H2O.
7. Destaining Buffer- 40% methnol, 10% Acetic Acid, 50% Ultra Pure H2O
Protocol:
1. Dilute 1 part sample with 1 part sample buffer.
2. Incubate at room temperature for 10 min.
3. Load samples into gel and run at 100V for 90 min (or until dye front reaches
bottom of the gel.
4. Place gels in renaturing buffer for 30 min at room temp.
5. Transfer gel to developing buffer and incubate for 30 min at room temp.
6. Transfer gel to fresh developing buffer and incubate at 37°C with gentle shaking
overnight.
7. Stain gel with staining buffer for 1 hour at room temp.
8. Destain until clear bands appear against blue background (30-60 min.).
a. Gel may shrink following detaining. To rehydrate gel prior to
photographing, incubate in Ultra Pure H2O until gel regains original size
(~10min).
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